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Abstract
Phosphodiesterase 4 catalyzes the hydrolysis of cyclic AMP and is a target for the development of
anti-inflammatory agents. We have designed and synthesized a series of phenyl alkyl ketones as
PDE4 inhibitors. Among them, 13 compounds were identified as having submicromolar IC50 values.
The most potent compounds have IC50 values of in the mid- to low-nanomolar range. Compound
5v also showed preference for PDE4 with selectivity of >2000-fold over PDE7, PDE9, PDE2, and
PDE5. Docking of 5v, 5zf, and 5za into the binding pocket of the PDE4 catalytic domain revealed
a similar binding profile to PDE4 with rolipram except that the fluorine atoms of the difluoromethyl
groups of 5v, 5za, and 5zf are within a reasonable range for hydrogen bond formation with the amide
hydrogen of Thr 333 and the long alkyl chain bears additional van der Waals interactions with His
160, Asp 318, and Tyr 159.
Introduction
Phosphodiesterases (PDEs) are responsible for the hydrolysis of second messengers cyclic
adenosine and guanosine monophosphates (cAMP and cGMP).a,1 Because of the important
roles that cAMP and cGMP play, PDEs are excellent targets for the development of therapeutic
agents. About 100 isoforms of PDEs are coded by 21 human genes and differentially expressed
in various cell types.2–7 Such a large number of isoforms presents a unique challenge to the
design and synthesis of PDE inhibitors that are specific for PDE isoforms of interest for
pharmaceutical applications. We are especially interested in developing PDE4 inhibitors
because of its implication in inflammatory diseases such as asthma and chronic obstructive
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pulmonary disease.3,8–13 PDE4 specifically catalyzes the hydrolysis of cAMP14 and has been
found in inflammatory15,16 as well in immune cells.17 Several selective PDE4 inhibitors have
entered into clinical trials, the results from which have validated PDE4 as a pharmacological
target for the development of therapeutic agents for the treatment of inflammatory and chronic
obstructive pulmonary diseases.18–22 Some PDE4 inhibitors, such as rolipram (Figure 1), have
been dropped from clinical studies because of side effects, which presumably arise from
nonspecific inhibition of other isoforms, while others including roflumilast and cilomilast
(Figure 1) are still in clinical trials.3,23,24 Up until now no PDE4 inhibitors have been approved
for clinical use.
We are interested in the design, synthesis, and evaluation of selective PDE4 inhibitors for
potential pharmaceutical applications. The design is based on published crystal structural
information.25 Forty-one potential PDE4 inhibitors have been designed, synthesized, and
evaluated. Figure 2 shows the core structure and different substituents in general terms.
Results and Discussion
Design
The design was based on published cocrystal structures of PDE4D2 and rolipram.25,26 From
the crystal structure, it was clear that the side chain region of rolipram still has plenty of space
for structural optimization and exploration of selectivity. Therefore, three series of compounds
with ketone, alcohol, and alkyl side chains as point of modification were designed with the
ketone series looking especially promising because of the planar structure of the side chain
moiety at the aryl attachment point. However, the other compounds also seemed like reasonable
candidates (Figure 2).
Chemical Synthesis
The synthesis of the designed analogues started with catechol, which required differential
alkylation of the two hydroxyl groups of the catechol core. Therefore, the synthesis started
with the alkylation of 1 at either the 3- or 4-position (Scheme 1). In one series, a difluoromethyl
group needed to be attached to the 4-position, which was achieved through the alkylation of
3,4-dihydroxybenzaldehyde using chlorodifluoroacetate to give 4-difluoromethoxy-3-
hydroxybenzaldehyde 2a in 45% yield and 3,4-bis(difluoromethoxy)benzaldehyde 3n in 20%
yield.27,28 For the series with methyl substitution at either the 3- or 4-position of the catechol
core, commercially available 3-hydroxy-4-methoxybenzaldehyde 2b or 4-hydroxy-3-
methoxybenzaldehyde 2c was used as the starting material. The second alkyl group on the
catechol moiety was attached by reacting 2a–c with racemic alcohols in THF via the Mitsunobu
reaction (method A) to give racemic compounds 3a–j or by O-alkylation with bromides
(method B) to give compounds 3k–m. Treatment of aldehydes 3a–m with n-butyllithium,
tert-butyllithium, or a Grignard reagent gave the corresponding diastereomeric mixtures of
alcohols 4a–w and 4za–zn. Oxidation of the alcohol with pyridium chlorochromate (PCC)
afforded the corresponding ketones 5a–v and 5za–zm. Reaction of 5g,h with pyridinyllithium
or quinolinyl-lithium gave the respective alcohols 6a,b. Dehydration of 6a afforded olefins
7a. Hydrogenation of 7a on Pd/C afforded 8.
Compounds 4h and 4i were converted to their respective chlorides 9a and 9b upon reaction
with thionyl chloride (Scheme 2). Reaction of 9a,b with the sodium salt of methyl acetoacetate
afforded a diastereomeric mixture of esters 10a,b. Saponification followed by acidification led
to spontaneous decarboxylation to give derivatives 11a,b (Scheme 2).
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SAR of Potential PDE4D Inhibitors
The enzyme inhibitory activities of the synthesized compounds were evaluated against PDE4
using human PDE4D2 (79–438) expressed in E. coli strain BL21 (Codonplus) as a model.25
The results are summarized in Tables 1–3.
The alcohol series of compounds (entries 1–5, Table 1) only exhibited weak inhibition activities
with IC50 values in the range from 10 μM to over 100 μM, which were many fold less potent
than the corresponding phenyl alkyl ketones (entries 9–12, 16, Table 2). Such results indicate
that a planar geometry is desirable at this position for compounds with the catechol core. The
inhibition results with the disubsituted alcohol (entry 6, Table 1) further suggested that the
planar geometry was required. With the additional group on 6b the inhibition potency did not
improve significantly compared to the ketone series. Within the alcohol series, there are two
substitution patterns: one with a bulky alkyl group on the 3-position and the other with a bulky
alkyl group on the 4-position of the catechol core. It is very clear that the compound (entry 5,
IC50 = 10 μM) with a small methyl group on the 4-position and the bulky substitution on the
3-position has much higher potency than the analogues with a reverse substitution pattern
(entries 1–4, IC50 > 100 μM). The same trend is reflected in the phenyl alkyl ketone series. For
example, the 4-methoxy substituted phenyl compounds (entries 14–21, Table 2) are 20- to 500-
fold more potent than the corresponding 3-methoxy substituted compounds (entries 7–12,
Table 2). Such results are consistent with literature reports as well.19
With the initial indication that the 4-methoxy ketones are more active, the subsequent effort
was focused on optimizing this series of compounds. One approach adopted was to use a 4-
difluoromethoxy group in place of the methoxy group with the idea of improved metabolic
stability (entries 24–28 and 33–35, Table 2).27,28 It turned out that these 4-difluoromethoxy
compounds were also 2- to 14-fold more potent than the corresponding 4-methoxy substituted
compounds (entries 14, 16, 18–20, and 37, Table 2). Within this series, the substituent effect
at the 3-position was also studied. The tetrahydrofuran-3-yloxy substituted phenyl compounds
(entries 16, 17) have 3-to 8.5-fold higher potencies than the corresponding tetrahydropyran-3-
yloxy substituted phenyl compounds (entries 14, 15). The replacement of the tetrahydrofuran
ring by a cyclopentyl ring (entry 25) gave a compound (entry 32) with comparable potency
(IC50 = 28 nM). The tetrahydrofuran-3-yloxy substituted phenyl compound (entry 28) also
seems to be more active than the corresponding Boc protected piperidi-4-nyl substituted
compound (entry 33) by more than 20- to 30-fold, and the 3,4-bis(difluoromethoxy)phenyl
compounds (entry 31) are also less active than the corresponding 4-difluoromethyl-3-
tetrahydrofuran-3-yloxy substituted phenyl compounds (entries 27, 28, 34, and 35) by 2.7- to
60-fold. Similarly, replacing the tetrahydrofuran ring with a deprotected tetrahydropyrrol ring
(entries 25, 28) also decreased the potency of IC50 by over 100 μM (entry 22) from 26 and 61
nM.
In the series of the 4-methoxy-3-tetrahydrofuran-3-yloxy phenyl ketones (entries 16–21, 37,
38) and the series of the 4-difluoromethoxy-3-tetrahydrofuran-3-yloxy phenyl ketones (entries
25–28 and 34–36), both ketones (entries 25, 37) with an isobutyl side chain have the highest
potency (IC50 of 26 and 176 nM, respectively) and the ketones (entries 28 and 16) with a butyl
side chain have the second highest potency (IC50 of 61 and 220 nM, respectively). The ketones
with the bulky cyclohexyl (entries 21 and 26) and phenylalkyl (entries 20 and 18) side chains
(R3) constantly showed the lowest potency.
We have also tested the compounds with further transformations of the ketone group into a
sp3 carbon (entries 39–41, Table 3). None of these transformations led to improved potency.
Some representatives of the PDE4 inhibitors were tested for their PDE4 selectivity using human
PDE7A1, 9A2, 2A3, and 5A1 subtypes, which were cloned and expressed in E. coli strain
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BL21 (Codonplus) (Table 4).25 Most of the compounds that we have synthesized showed high
PDE4 selectivity. For example, 5v showed preference for PDE4 with selectivity of at least
about 2000-fold over PDE7A1, PDE9A2, PDE2A3, and PDE5A1, respectively; 5k had
selectivity at least 14-fold over PDE7A1, PDE9A2, PDE2A3, and PDE5A1.
The inhibition of TNF-α production induced by lipopolysaccharide is an essential assay for
evaluation of the pharmacological effect of PDE4 inhibitors in anti-inflammation and the
treatment of COPD and asthma.29,30 Normal and nonstimulated human blood does not contain
detectable levels of TNF-α. Upon stimulation with LPS, activated monocytes express and
secrete TNF-α for up to 8 h and plasma levels remain stable for 24 h. Published studies have
shown that inhibition of TNF-α production by increasing intracellular cAMP via PDE4
inhibition and/or enhanced adenylyl cyclase activity occurs at the transcriptional level.
Therefore, we selected the two most active compounds and studied their ability to inhibit TNF-
α production. Specifically, the effect of 5v and 5zf for their ability to inhibit LPS-mediated
TNF-α production by human peripheral blood mononuclear cells (PBMCs) was studied (Figure
3). Rolipram (IC50 = 60 nM) was included as a reference. The results show that both 5v and
5zf were able to inhibit LPS-mediated TNF-α production with IC50 values of 40 and 100 nM,
respectively. IC50 values for TNF-α release from the literature may not be directly comparable
because of variations of assay systems and conditions. However, if roliprarn is taken as a
relative reference, the potency of our 5v is higher than that of rolipram,30 a compound that
went into clinical trials for treatment of COPD.
Molecular Modeling
In an effort to gain an understanding of the structural basis for the empirical structure–activity
relationships observed, we also studied the binding of the synthesized inhibitors with PDE4D2
through computer modeling. The crystal structure of PDE4D2–rolipram complex25,26 was
used as the starting point.
Molecular Docking
In this investigation, the 3D structure of PDE4D was taken from a Protein Data Bank entry
(PDB entry 1OYN) having the ligand rolipram in place.26 The new inhibitors were built and
optimized at the Hartree–Fock level with the 6-311 G basis set in the Gaussian 03 program.
31 The optimized ligands were then embedded with Gastiger–Hückel partial charges using the
SYBYL 7.1 package.30 DOCK 5.232 was employed to dock these ligands into the PDE4D
active site. The resulting structures were then analyzed using HBPLUS 3.0633 and Ligplot
4.2234 programs to identify specific contacts between ligands and receptor.
Initially, we selected the most potent compounds 5v, 5za, and 5zf for the docking experiments.
These three compounds adopt the same alignments as rolipram in the active site. Such
alignments have also been confirmed by a preliminary crystallographic study, the details of
which will be published elsewhere. Figure 4 presents the docking conformations of rolipram
(white), 5za (yellow), 5v (blue), and 5zf (red) in the active site of PDE4. Figure 5 depicts a
schematic binding profile of 5za. Similar to the binding of rolipram (Figure 5), 5za, 5v, and
5zf have a hydrogen bond with Gln 369 and hydrophobic contact with Ile 336, Met 357, Phe
340, Ser 368, Met 337, Phe 372, and Tyr 3. Different from rolipram binding are the possible
interactions of the difluoromethyl group of 5za, 5v, and 5zf with the Thr 333 N–H, which could
engage in hydrogen bond interactions, and the additional van der Waals interactions of the long
alkyl chain with His 160, Asp 318, and Tyr 159. In the case of hydrogen bond interactions, the
F–O distance is 2.68 Å but with a nonideal C–F–H angle of 34.7°.
The computer modeling results are also consistent with the empirically observed structure–
activity relationship. From the modeling results it is clear that the 4-methyl/difluoromethyl
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group occupies a small pocket. Anything larger at this position would result in steric hindrance
and therefore unfavorable interactions (Figure 6). Such a finding is consistent with earlier
studies with rolipram26 and the fact that 4-position substitution with a bulkier group leads to
compounds with diminished potency (entries 1–6, Table 1; entries 7–12, Table 2). Figure 6
shows the unfavorable interactions of an inhibitor with large substituents at the 4-position. For
5za, the difluoromethyl group has an additional hydrogen bond with Thr 333; meanwhile, the
long alkyl chain also bears additional van der Waals interactions with His 160, Asp 318, and
Tyr 159. This difference could be the reason that these difluoremethyl compounds have higher
potencies than others (Figures 5 and 7). The 3-position has a fairly large hydrophobic pocket,
allowing favorable interactions with bulkier groups such as tetrahydropyran and
tetrahydrofuran (entries 13–28, 32–38, Table 2). At this site, there is Lys 367, which under
normal physiological conditions should be positively charged. This helps to explain why the
deprotected amino group in compound 5i (entry 22, Table 2), which introduces a positively
charged protonated amine, leads to reduced potency.
Within the ketone series (entries 7–38, Table 2), it seems that compounds with a four-carbon
side chain have the highest potency. This is consistent with the existence of a hydrophobic
binding pocket accommodating the side chain, which is somewhat narrow but deep. Bulkier
groups such as the phenyl and cyclohexyl side chains protrude away from this hydrophobic
pocket, resulting in unfavorable interactions (Figures 4 and 7). The planar sp2-hybridized
ketone group seems to have the flexibility to put the hydrophobic side chain in the right position
and orientation for favorable hydrophobic interactions. In contrast, a tetrahedral sp3 carbon
would fix the side chain in a position for less favorable hydrophobic contact with PDE4, which
explains why the compounds with a sp3 carbon at the benzylic position showed low potency
(Figure 8).
Molecular Similarity Index Analysis (CoMSIA)
In order to achieve some semiquantitative understanding of the contribution of various
parameters to binding affinity, we have also conducted a structure-based comparative
molecular similarity index analysis (CoMSIA) implemented in SYBYL 7.1.30 CoMSIA is an
extension of the CoMFA (comparative molecular field analysis) methodology.35,36 Both are
forms of 3D-QSAR and are based on the assumption that changes in ligand binding affinities
are related to changes in molecular properties, represented by fields. They differ only in the
implementation of the fields.35,36 In this study the docking conformations of all compounds
synthesized were used as the input of molecular alignments (Figure 9).
The CoMSIA model analysis indicates that the contribution of steric, electrostatic,
hydrophobic, hydrogen bond donor, and hydrogen bond acceptor of this series of PDE4
inhibitors to binding affinity is 5.8%, 26.4%, 25.4%, 23.7%, and 18.7%, respectively. In PLS
analysis, the standard error of estimate of 0.312, non-cross-validated correlation coefficient
r2 of 0.939, cross-validated coefficient q2 of 0.832, and F value of 584.051 show that our
CoMSIA model has good prediction. In order to validate this CoMSIA model again, we
introduced an external test set consisting of rolipram plus nine compounds (s1–s9) from
literature (Figure 10).19 After prediction by the CoMSIA model, an r2 of 0.803 and q2 of 0.706
were obtained. This external validation again suggests a reliable CoMSIA model we harvested.
Table 5 shows a comparison of the calculated pIC50 and experimentally determined pIC50
values using the CoMSIA model developed, and Figure 11 shows the schematic correlation of
such data. Such results will help future optimization efforts.
NMR Studies of the Interactions of 5i with PDE4D2 Protein
In order to achieve some experimental verification of the modeled binding modes of the
inhibitors synthesized, NMR experiments were conducted in solution. We initially selected
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two compounds, 5i (IC50 = 102 μM) and 5zi (IC50 = 40 μM), for the studies. These two
compounds have moderate affinities, which allow high sensitivity detection of transferred
effects through observation of spectra from ligands in 10- to 100-fold excess over protein.37
Under the conditions of rapid exchange, normally associated with low to moderate binding
affinities, effects such as nuclear Overhauser effects (NOEs) and saturation transfer differences
(STDs) originating with ligands bound to PDE4 are carried into solution. Because of enhanced
efficiencies in magnetization transfer in large complexes, the bound-state properties dominate
the average effects observed through the narrow lines and high intensities of the free ligand
resonances. Unfortunately, 5zi had solubility and nonspecific binding problems that prevented
the collection of meaningful data. Therefore, only 5i was used for the NMR studies. Both STD
and transferred NOEs (trNOE) experiments were performed to study the inhibitor. STD
provides information on the proximity of protons on the bound ligand to protons on the protein.
The relative signal intensities in an STD spectrum are interpreted to produce an epitope map
with protons giving the strongest signal closest to the protein surface.37 The trNOE experiment
provides distance information between protons within the ligand, which can be used to
determine the compound’s bound state conformation.37 The solubility of 5i (up to 800 μM in
D2O) was confirmed by NMR. A reference 1H spectrum allowed assignment of resonances as
indicated in Figure 12a.
The STD spectrum of 5i in the presence of PDE4D2 is presented in Figure 12b. In an effort to
map the binding epitope, the peak integrals from the reference and STD spectra were compared
and normalized to give a STD percentage for each proton. The STD percentages are shown on
the chemical structure in Figure 12b. The STD percentages give an indication of which protons
of bound 5i are close to the protein, i.e., an epitope map. For 5i, peak “i” was not observed in
the STD spectrum, indicating that it does not bind PDE4D2 providing evidence that it is a
contaminant. The n-butanyl, methyl, and catechol protons show stronger STD contacts than
the piperidinyl protons. While it is possible to check these intensities for consistencies with
specific models when available,38 it is also useful to seek a more qualitative interpretation. The
results as presented are consistent with computer modeling studies indicating strong
hydrophobic interactions of the alkyl chain and adjacent parts of the catechol ring. Close
approach combined with the higher density of nonexchangeable protons on hydrophobic
groups would lead to the observed effects.
A trNOEsy spectrum of 5i in the presence of PDE4D2 is presented in Figure 13. A short mixing
time of 50 ms was used to avoid spin diffusion artifacts and provide a more accurate
interpretation. The cross peaks show the same sign as the diagonal peaks indicating negative
NOEs originating from the bound form of 5i. The reference NOESY spectrum of 5i (not shown)
has positive NOEs typical of small molecules free in solution and confirms that the NOEs in
the trNOEsy spectrum reflect the bound state structure. The appearance of a set of cross peaks
similar to those seen in the reference NOESY spectrum is indicative of some similarity in the
bound form compared to the solution form of the drug. Under an initial rate assumption, the
relative intensities of the NOESY cross peaks are inversely related to the sixth power of the
distance between proton pairs and qualitative information on a structure can readily be
determined by comparing the cross peak intensities in Figure 13. Structurally restraining NOEs
include contacts between the catechol protons and the methyl, piperidinyl, and n-butanyl
protons. The catechol proton in the 6-position (peak “a”) has an NOE to the n-butanyl protons
(peak “g”), and the catechol proton in the 5-position (peak “c”) has an NOE to the methyl
protons (peak “d”). This NOE would suggest a conformation different from the structure used
to illustrate the NMR spectrum (Figure 12) with the keto chain rotated 180° about the chain to
catechol bond. This geometry is in fact consistent with the geometries shown for 5v, 5za, and
5zf (Table 2). NOEs are also seen from the catechol 2-position to the piperidinyl protons in
the 4-position (peak “h”) and the NMR equivalent methylene protons in the 3- and 5-positions
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(peaks “j” and “k”). This NOE restrains the relative orientation of the piperidinyl and catechol
rings and is consistent with the docking models of 5za in Figure 7.
Conclusions
A new series of phenyl alkyl ketones with variable side chains was investigated as potential
PDE4D inhibitors. Thirteen alkyl ketones were identified to have submicromolar IC50 values.
Among them, the most potent compounds 5v, 5zf, and 5za have IC50 values of 26, 28, and 61
nM, respectively. Compound 5v also showed a preference for PDE4D with selectivity of >2000
fold over PDE7A1, PDE9A2, PDE2A3, and PDE5A1, respectively. Docking of 5v, 5zf, and
5za into the binding pocket of the PDE4 catalytic domain revealed a similar binding profile
with PDE4 as rolipram. trNOEsy and STD NMR experiments on 5i provided experimental
support for many of the modeling projections. Compound 5i appears to adopt the same overall




All reagents were purchased from Acros and Aldrich. N-(tert-Butoxycarbonyl)-4-piperidinol
was synthesized according to literature procedures.1 Microwave heating was performed in the
single-mode microwave cavity of a Discover Synthesis System (CEM Co.), and all microwave
reactions were conducted in a heavy-walled glass vials sealed with Teflon septa. 1H
NMR, 13C NMR, and DEPT spectra were recorded at 400 and 100 MHz, respectively, on a
Bruker 400 NMR spectrometer. Combustion analyses and mass spectra were performed by the
analytical and the mass spectrometry facilities at Georgia State University.
4-Difluoromethoxy-3-hydroxybenzaldehyde (2a) and 3,4-Bisdifluoromethoxybenzaldehyde
(3n)
A mixture of 3,4-dihydroxybenzaldehyde (1.38 g, 0.01 mol), methyl chlorofluoroacetate (1.87
g, 0.013 mol), and cesium carbonate (4.24 g, 0.013 mol) in DMF (20 mL) was stirred at 65 °
C for 3 h under nitrogen atmosphere. Then DMF was removed in vacuo and the residue was
partitioned between aqueous 3 N HCl and ether. The aqueous layer was extracted three times
with ether. The combined organic solution was washed with water and brine, dried over
MgSO4, filtered, and evaporated. The residue was purified by flash chromatography to afford
2a as a white solid (0.85 g, 45%) and 3n as a yellowish liquid (0.48 g, 20%).
2a
1H NMR (CDCl3): 9.92 (1H, s), 7.55 (1H, d, J = 4.0 Hz), 7.45 (1H, dd, J = 4.0 and 8.4 Hz),
7.28 (1H, d, J = 8.4 Hz), 6.67 (1H, t, J = 72.8 Hz), 6.17 (1H, s, br). 13C NMR (CDCl3): 191.1
(d), 147.8 (s), 143.0 (s), 134.5 (s), 123.2 (d), 119.3 (d), 117.1 (d), 115.6 (triplet, J = 262 Hz,
d). MS-EI: 188 (M+).
3n
1H NMR (CDCl3): 9.95 (1H, s), 7.79–7.77 (2H, m), 7.43 (1H, dd, J = 8.8 Hz), 6.68 (1H, t, J
= 72.4 Hz), 6.63 (1H, t, J = 72.8 Hz). 13C NMR (CDCl3): 190.1 (d), 147.1 (s), 142.3 (s), 134.1
(s), 128.7 (d), 122.1 (d), 121.4 (d), 115.5 (triplet, J = 263 Hz, d), 115.3 (triplet, J = 262 Hz, d).
MS-EI: 238 (M+).
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General Procedure for the Synthesis of 3 by Mitsunobu Reaction of 2a and 2c with R2OH
To the mixture of compound 2 (1 mmol), R2OH (1.1 mmol), and di-tert-butyl azodicarboxylate
(1.2 mmol) in THF (5 mL) was added dropwise triphenylphosphine (1.2 mmol) in THF (5 mL)
at 0 °C. The resulting solution was stirred until compound 2 was consumed completely (usually
within 24 h). Solvent was removed in vacuo and the residue was purified by flash
chromatography to afford 3.
4-Difluoromethoxy-3-(tetrahydropyran-4-yloxy)benzaldehyde (3a)
Yield: 28%. 1H NMR (CDCl3): 9.93 (1H, s), 7.52 (1H, d, J = 2.0 Hz), 7.48 (1H, dd, J = 2.0
and 8.0 Hz), 7.33 (1H, d, J = 8.0 Hz), 6.70 (1H, t, J = 74.0 Hz), 4.65 (1H, m), 3.98 (2H, m),
3.61 (2H, m), 2.06 (2H, m), 1.85 (2H, m). 13C NMR (CDCl3): 190.6 (d), 149.2 (s), 146.0 (s),
134.4 (s), 125.0 (d), 122.3 (d), 115.6 (triplet, J = 259 Hz, d), 114.1 (d), 73.3 (d), 64.7 (t), 31.4
(t). MS-EI: 272 (M+)
4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)benzaldehyde (3b)
Yield: 84%. 1H NMR (CDCl3): 9.93 (1H, s), 7.48 (1H, dd, J = 1.6 and 8.4 Hz), 7.44 (1H, d,
J = 1.6 Hz), 7.33 (1H, d, J = 8.4 Hz), 6.67 (1H, t, J = 74.4 Hz), 5.07 (1H, m), 4.06–3.91 (4H,
m), 2.30 (1H, m), 2.19 (1H, m). 13C NMR (CDCl3): 190.5 (d), 149.4 (s), 145.6 (s), 134.3 (s),
125.2 (d), 122.2 (d), 115.5 (triplet, J = 260 Hz, d), 112.9 (d), 78.8 (d), 72.5 (t), 67.0 (t), 32.7
(t). MS-EI: 258 (M+).
4-(2-Difluoromethoxy-5-formylphenoxy)piperidine-1-carboxylic Acid tert-Butyl Ester (3c)
Yield: 54%. 1H NMR (CDCl3): 9.93 (1H, s), 7.52 (1H, s), 7.48 (1H, dd, J = 1.2 and 8.4 Hz),
7.33 (1H, d, J = 8.4 Hz), 6.66 (1H, t, J = 74.0 Hz), 4.63 (1H, m), 3.69 (2H, m), 3.41 (2H, m),
1.96 (2H, m), 1.81 (2H, m), 1.48 (9H, s). 13C NMR (CDCl3): 190.6 (d), 154.6 (s), 149.3 (s),
146.0 (triplet, J = 3 Hz, s), 134.5 (s), 125.2 (d), 122.3 (d), 115.6 (triplet, J = 260 Hz, d), 114.1
(d), 79.7 (s), 74.0 (d), 40.4 (multiple, t), 30.2 (t), 28.3 (q).
3-Methoxy-4-(tetrahydropyran-4-yloxy)benzaldehyde (3d)
Yield: 65%. 1H NMR (CDCl3): 9.85 (1H, s), 7.43–7.42 (2H, m), 7.01 (1H, d, J = 8.8 Hz), 4.62
(1H, m), 4.03 (2H, m), 3.93 (3H, s), 3.59 (2H, m), 2.07 (2H, m), 1.89 (2H, m). 13C NMR
(CDCl3): 190.7 (d), 152.2 (s), 150.7 (s), 130.4 (s), 126.1 (d), 114.0 (d), 110.0 (d), 73.2 (d), 65.1
(t), 56.0 (q), 31.7 (t). MS-EI: 236 (M+).
3-Methoxy-4-(tetrahydrofuran-3-yloxy)benzaldehyde (3e)
Yield: 71%. 1H NMR (CDCl3): 9.84 (1H, s), 7.44–7.41 (2H, m), 6.93 (1H, d, J = 8.4 Hz), 5.06
(1H, m), 4.02 (4H, m), 3.90 (3H, s), 2.06 (2H, m). 13C NMR (CDCl3): 190.4 (d), 152.1 (s),
150.0 (s), 130.0 (s), 125.8 (d), 112.8 (d), 109.5 (d), 78.4 (d), 72.4 (t), 66.8 (t), 55.5 (q), 32.6
(t). MS-EI: 222 (M+).
4-(4-Formyl-2-methoxyphenoxy)piperidine-1-carboxylic Acid tert-Butyl Ester (3f)
Yield: 76%. 1H NMR (CDCl3): 9.85 (1H, s), 7.44–7.41 (2H, m), 7.03 (1H, m), 4.61 (1H, m),
3.91 (3H, s), 3.77 (2H, m), 3.32 (2H, m), 1.97 (1H, m), 1.82 (1H, m), 1.46 (9H, s). 13C NMR
(CDCl3): 190.7 (d), 154.6 (s), 152.1 (s), 150.7 (s), 130.3 (s), 126.1 (d), 114.1 (d), 110.0 (d),
79.5 (s), 73.7 (d), 56.0 (q), 40.5 (multiple, t), 30.3 (t), 28.3 (q).
4-Methoxy-3-(tetrahydropyran-4-yloxy)benzaldehyde (3g)
Yield: 52%. 1H NMR (400 MHz, CDCl3): 1.84–1.86 (2H, q, J = 4.4, 4.4 Hz), 2.06 (2H, d, J =
8.8 Hz), 3.57 (2H, t, J = 9.2 Hz), 3.95 (3H, s), 4.05 (2H, m), 4.51 (1H, m), 7.01 (1H, d, J = 8.4
Hz), 7.44 (1H, s), 7.47–7.49 (1H, q, J = 1.6, 6.4 Hz) 9.84 (1H, s) ppm. 13C NMR (100 MHz,
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CDCl3): 31.86, 56.16, 65.31, 73.49, 111.25, 113.92, 127.15, 1.99, 147.09, 156.06, 190.80 ppm.
HRMS (ESI+): calcd for C13H16O4, 237.1127; found, 237.1121.
4-Methyoxy-3-(tetrahydrofuran-3-yloxy)benzaldehye (3h)
Yield: 40%. 1H NMR (400 MHz, CDCl3): 2.25 (2H, q, J = 6.0, 8.0 Hz), 3.94 (4H, d, J = 12
Hz), 4.04 (3H, d, J = 2.4 Hz), 5.02 (1H, s), 7.00 (1H, d, J = 8.0 Hz), 7.35 (1H, s), 7.48 (1H, q,
J = 2.0, 6.4 Hz), 9.84 (1H, s) ppm. 13C NMR (100 MHz, CDCl3): 32.98, 56.16, 67.72, 72.91,
78.67, 111.07, 112.18, 127.21, 1.96, 147.58, 155.56, 190.73 ppm. HRMS (ESI+): calcd for
C12H14O4, 223.0970; found, 223.0965.
4-(5-Formyl-2-methoxyphenoxy)piperidine-1-carboxylic Acid tert-Butyl Ester (3i)
Yield: 53%. 1H NMR (400 MHz, CDCl3): 1.47 (9H, s), 1.80 (2H, q, J = 3.2, 3.6 Hz), 1.95 (2H,
q, J = 4.0, 4.8 Hz), 3.30 (2H, m), 3.80 (2H, s), 3.94 (3H, s), 4.52 (1H, s), 7.01 (1H, d, J = 8.0
Hz), 7.44 (1H, s), 7.49 (1H, d, J = 8.0 Hz), 9.84 (1H, s) ppm. 13C NMR (100 MHz, CDCl3):
28.45, 30.61, 56.17, 74.20, 79.62, 111.26, 114.11, 127.21, 130.04, 147.16, 154.78, 156.13,
190.79 ppm. HRMS (ESI+): calcd for C18H25NO5, 336.1811; found, 336.1814.
tert-Butyl 3-(2-(Difluromethoxy)-5-formylphenoxy)pyrrolidine-1-carboxylate (3j)
Yield: 26%. 1H NMR (400 MHz, CDCl3): 1.46 (9H, s), 2.20 (2H, d, J = 7.6 Hz), 3.65–3.49
(4H, m), 5.01 (1H, s), 6.59 (1H, (d) t, J = 74 Hz), 7.32 (1H, s), 7.45 (1H, s), 7.49 (1H, d, J =
8.4 Hz), 9.26 (1H, s) ppm. 13C NMR (100 MHz, CDCl3): 28.46, 31.53 (d), 44.00 (d), 51.47
(d), 79.72 (d), 113.54 (d), 122.53 (d), 125.64, 154.54, 190.55 ppm. HRMS (ESI+): calcd for
C13H13F2NO5 (M+ – tert-butyl), 302.0840; found, 302.0823.
3-Cyclopentyloxy-4-difluoromethoxybenzaldehyde (3k)
A mixture of 4-difluoromethoxy-3-hydroxybenzaldehyde 2a (0.38 g, 2.0 mmol), cyclopentyl
bromide (0.45 g, 3.0 mmol), and potassium carbonate (0.41 g, 3.0 mmol) in DMF (10 mL) was
stirred overnight at 65 °C. After the mixture was filtered, solvent was removed in vacuo and
the residue was purified by flash chromatography to afford 3-cyclopentyloxy-4-
difluoromethoxybenzaldehyde (0.18 g, 35%). 1H NMR (CDCl3): 9.93 (1H, s), 7.48 (1H, d, J
= 1.6 Hz), 7.43 (1H, dd, J = 1.6 and 8.0 Hz), 7.00 (1H, d, J = 8.0 Hz), 6.65 (1H, t, J = 74.8
Hz), 4.90 (1H, m), 1.98–1.80 (6H, m), 1.67 (2H, m). 13C NMR (CDCl3): 190.9 (d), 150.1 (s),
145.7 (s), 134.5 (s), 124.4 (d), 122.4 (d), 115.7 (triplet, J = 259 Hz, d), 113.3 (d), 80.9 (d), 32.7
(t), 23.9 (t).
General Procedure for the Preparation of 3- or 4-(Pyridine-2-yloxy)benzaldehydes (3l or 3m)
A mixture of 4-difluoromethoxy-3-hydroxybenzaldehyde 2a (2.0 mmol) or 2c, 2-
bromopyridine (0.95 g, 6.0 mmol), and potassium carbonate (0.41 g, 3.0 mmol) in DMSO (1
mL) was heated under microwave irradiation for 10 min. After the solvent was removed in
vacuo, the residue was purified by flash chromatography to afford the 3-(pyridine-2-yloxy)
benzaldehyde 3l or 3m.
4-Difluoromethoxy-3-(pyridine-2-yloxy)benzaldehyde (3l)
Yield: 11%. 1H NMR (CDCl3): 9.94 (1H, s), 8.09 (1H, m), 7.78–7.72 (3H, m), 7.41 (1H, d,
J = 8.8 Hz), 7.06–7.02 (2H, m), 6.52 (1H, t, J = 74.0 Hz). 13C NMR (CDCl3): 190.1 (d), 162.6
(s), 148.3 (s), 147.2 (d), 145.5 (s), 139.8 (d), 134.5 (s), 127.7 (d), 124.4 (d), 121.3 (d), 119.2
(d), 118.3 (d), 115.7 (triplet, J = 260 Hz, d), 117.4 (d). MS-EI: 264 (M+).
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Yield: 85%. 1H NMR (CDCl3): 9.95 (1H, s), 8.13 (1H, m), 7.71 (1H, m), 7.54–7.50 (2H, m),
7.00 (1H, d, J = 8.0 Hz), 7.02–6.99 (2H, m), 3.83 (3H, s). 13C NMR (CDCl3): 191.0 (d), 162.9
(s), 152.3 (s), 148.2 (s), 147.4 (d), 139.4 (d), 134.1 (s), 125.1 (d), 122.9 (d), 118.7 (d), 111.3
(d), 111.1 (d), 55.9 (q). MS-EI: 198 (M+).
General Procedure for the Synthesis of 4 by Nucleophilic Addition to Aldehydes 3
To aldehyde 3 (1 mmol) in THF (5 mL) was added dropwise n-butyllithium or Grignard reagent
at −78 °C. The resulting mixture was stirred overnight, allowing the temperature too gradually
warm from −78 °C to room temperature, and then quenched with water. The aqueous layer
was extracted three times with ethyl acetate. The combined organic solution was dried over
MgSO4, filtered, and evaporated. The residue was purified by flash chromatography to afford
4.
4-[4-(1-Hydroxypentyl)-2-methoxyphenoxy]piperidine-1-carboxylic Acid tert-Butyl Ester (4a)
Yield: 42%. 1H NMR (CDCl3): 6.91 (1H, d, J = 2.0 Hz), 6.87 (1H, d, J = 8.0 Hz), 6.81 (1H,
dd, J = 2.0 and 8.0 Hz), 4.59 (1H, t, J = 6.8 Hz), 4.37 (1H, m), 3.84 (3H, s), 3.76 (2H, m), 3.23
(2H, m), 2.25 (1H, s, br), 1.89 (2H, m), 1.79–1.73 (4H, m), 1.46 (9H, s), 1.43–1.24 (4H, m),
0.89 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 154.7 (s), 150.9 (s), 145.6 (s), 139.3 (s), 118.1
(d), 117.5 (d), 109.9 (d), 79.4 (s), 74.5 (d), 74.3 (d), 55.8 (q), 40.6 (t), 38.7 (t), 30.7 (t), 28.3
(q), 27.8(t), 22.5 (t), 13.9 (q). MS-EI: 393 (M+).
1-[3-Methoxy-4-(tetrahydropyran-4-yloxy)phenyl]butan-1-ol (4b)
Yield: 70%. 1H NMR (CDCl3): 6.91 (1H, s), 6.87 (1H, d, J = 8.0 Hz), 6.81 (1H, d, J = 7.6 Hz),
4.59 (1H, m), 4.36 (1H, m), 3.98 (1H, m), 3.84 (3H, s), 3.50 (2H, m), 2.32 (1H, s, br), 1.97
(2H, m), 1.82–1.76 (3H, m), 1.64 (1H, m), 1.42 (1H, m), 1.31 (1H, m), 0.93 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 150.9 (s), 145.5 (s), 139.3 (s), 118.0 (d), 117.4 (d), 109.9 (d), 74.0
(d), 73.8 (d), 65.3 (t), 55.8 (q), 41.1 (t), 32.0 (t), 19.0 (t), 13.9 (q). MS-EI: 280 (M+).
1-[3-Methoxy-4-(tetrahydropyran-4-yloxy)phenyl]pentan-1-ol (4c)
Yield: 68%. 1H NMR(CDCl3): 6.92 (1H, s), 6.88 (1H, d, J = 8.0 Hz), 6.82 (1H, d, J = 8.0 Hz),
4.59 (1H, m), 4.38 (1H, m), 4.00 (2H, m), 3.86 (3H, s), 3.53 (2H, m), 1.99 (3H, m), 1.83–1.67
(4H, m), 1.36–1.25 (4H, m), 0.89 (3H, t, J = 6.8 Hz). 13C NMR (CDCl3): 151.0 (s), 145.7 (s),
139.2 (s), 118.1 (d), 117.4 (d), 110.0 (d), 74.4 (d), 73.9 (d), 65.4 (t), 55.9 (q), 38.7 (t), 32.1 (t),
28.1 (t), 22.6 (t), 13.9 (q). MS-EI: 4 (M+).
1-[3-Methoxy-4-(tetrahydrofuran-3-yloxy)phenyl]butan-1-ol (4d)
Yield: 77%. 1H NMR (CDCl3): 6.90 (1H, s), 6.80 (1H, d, J = 8.0 Hz), 6.75 (1H, d, J = 8.0 Hz),
4.90 (1H, m), 4.57 (1H, m), 3.99–3.82 (7H, m), 2.66 (1H, s, br), 2.14 (2H, m), 1.74 (1H, m),
1.63 (1H, m), 1.41 (1H, m), 1.00 (1H, m), 0.92 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 150.6
(s), 145.8 (s), 139.0 (s), 117.9 (d), 115.4 (d), 109.8 (d), 78.7 (d), 73.8 (d), 72.7 (t), 66.9 (t), 55.7
(q), 41.1 (t), 32.8 (t), 18.9 (t), 13.8 (q). MS-EI: 266 (M+).
1-[3-Methoxy-4-(tetrahydrofuran-3-yloxy)phenyl]pentan-1-ol (4e)
Yield: 66%. 1H NMR (CDCl3): 6.90 (1H, s), 6.81 (1H, d, J = 8.0 Hz), 6.76 (1H, d, J = 8.0 Hz),
4.90 (1H, m), 4.56 (1H, m), 4.00–3.83 (7H, m), 2.54 (1H, s, br), 2.14 (2H, m), 1.76 (1H, m),
1.67 (1H, m), 1.35–1.23 (4H, m), 0.88 (3H, t, J = 6.8 Hz). 13C NMR (CDCl3): 150.1 (s), 145.8
(s), 139.0 (s), 118.0 (d), 115.4 (d), 109.8 (d), 78.7 (d), 74.1 (d), 72.8 (t), 67.0 (t), 55.7 (q), 38.7
(t), 32.9 (t), 27.9 (t), 22.4 (t), 13.9 (q). MS-EI: 280 (M+).
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Yield: 45%. 1H NMR (CDCl3): 8.06 (1H, dd, J = 1.2 and 4.8 Hz), 7.57 (1H, m), 7.03 (1H, d,
J = 8.0 Hz), 7.01 (1H, d, J = 2.0 Hz), 6.90–6.85 (2H, m), 6.81 (1H, d, J = 8.0 Hz), 4.60 (1H,
m), 3.69 (3H, s), 2.89 (1H, s, br), 1.76 (2H, m), 1.43–1.31 (4H, m), 0.88 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 163.6 (s), 151.5 (s), 147.2 (d), 143.1 (s), 141.7 (s), 138.8 (d), 122.4
(d), 118.3 (d), 117.7 (d), 110.8 (d), 110.3 (d), 73.9 (d), 55.7 (q), 38.6 (t), 27.8 (t), 22.3 (t), 13.7
(q).
1-[3-Methoxy-4-(pyridin-2-yloxy)phenyl]butan-1-ol (4g)
Yield: 80%. 1H NMR (CDCl3): 8.11 (1H, dd, J = 2.0 and 5.2 Hz), 7.63 (1H, m), 7.07 (1H, d,
J = 8.0 Hz), 7.03 (1H, s), 6.94–6.87 (3H, m), 4.65 (1H, t, J = 6.0 Hz), 3.75 (3H, s), 2.40 (1H,
s, br), 1.78 (1H, m), 1.69 (1H, m), 1.46 (1H, m), 1.36 (1H, m), 0.94 (3H, t, J = 7.2 Hz). 13C
NMR (CDCl3): 163.6 (s), 151.6 (s), 147.4 (d), 143.0 (s), 141.5 (s), 139.1 (d), 122.6 (d), 118.4
(d), 117.9 (d), 110.5 (d), 110.3 (d), 74.0 (d), 55.8 (q), 41.1 (t), 19.0 (t), 13.9 (q). HRMS-ESI
(+): calcd for C16H20NO3, 274.1443; found, 274.1431 [M +H]+.
[3-Methoxy-4-(pyridin-2-yloxy)phenyl]quinolin-3-ylmethanol (4h)
Yield: 68%. 1H NMR (CDCl3): 8.75 (1H, d, J = 1.2 Hz), 8.16 (1H, s), 8.03–8.00 (2H, m), 7.74
(1H, d, J = 8.0 Hz), 7.65–7.59 (2H, m), 7.48 (1H, m), 7.09 (1H, d, J = 1.6 Hz), 7.04 (1H, d,
J = 8.0 Hz), 6.94–6.84 (3H, m), 5.95 (1H, s), 5.76 (1H, s, br), 3.63 (3H, s). 13C NMR
(CDCl3): 163.4, 151.7, 149.9, 147.2, 146.8, 141.8, 141.2, 139.3, 137.0, 133.1, 1.3, 128.5, 127.9,
127.7, 126.7, 122.7, 119.3, 118.1, 111.0, 110.6, 73.4, 55.7. MS-ESI (+): 359.58 [M + H]+.
[3-Methoxy-4-(pyridin-2-yloxy)phenyl]pyridin-3-ylmethanol (4i)
Yellow oil. Yield: 40%. 1H NMR (CDCl3): 8.51 (1H, s), 8.33 (1H, d, J = 3.6 Hz), 8.03 (1H,
m), 7.72 (1H, m), 7.62 (1H, m), 7.22 (1H, m), 7.07–7.05 (2H, m), 6.93–6.85 (3H, m), 5.78
(1H, s), 5.26 (1H, s, br), 3.67 (3H, s). 13C NMR (CDCl3): 163.4 (s), 151.7 (s), 147.9 (d), 147.8
(d), 147.1 (d), 141.7 (s), 141.4 (s), 139.9 (s), 139.2 (d), 134.5 (d), 123.4 (d), 122.6 (d), 119.0
(d), 118.0 (d), 110.9 (d), 110.6 (d), 73.1 (d), 55.7 (q).
1-[4-Methoxy-3-(tetrahydropyran-4-yloxy)phenyl]butan-1-ol (4j)
Yellow oil. Yield: 60%. 1H NMR (400 MHz, CDCl3): 0.92 (3H, t, J = 7.6 Hz), 1.44 (3H, m),
1.68 (1H, m), 1.87 (4H, m), 2.01 (2H, m), 3.56–3.51 (2H, dd, J = 2.4, 8.8 Hz), 3.84 (3H, s),
4.03 (2H, m), 4.44 (1H, m), 4.59 (1H, s), 6.86 (1H, d, J = 8.4 Hz), 6.92 (1H, d, J = 8.4 Hz),
6.95(1H, s) ppm. 13C NMR (100 MHz, CDCl3): 13.97, 19.10, 32.12, 41.24, 56.05, 65.38, 73.80,
73.96, 112.10, 115.34, 119.66, 137.75, 146.40, 150.28 ppm. HRMS (ESI+): calcd for
C16H22O3-H2O, 263.1647; found, 263.1645.
1-[4-Methoxy-3-(tetrahydropyran-4-yloxy)phenyl]pentan-1-ol (4k)
Yellow oil. Yield: 72%. 1H NMR (400 MHz, CDCl3): 0.88 (3H, t, J = 6.8 Hz), 1.25 (1.32 (3H,
m), 1.65 (1H, m), 1.85 (4H, m), 2.01 (2H, s), 3.53 (2H, t, J = 8.8 Hz), 3.84 (3H, s), 4.01 (2H,
t, J = 5.6 Hz), 4.43 (1H, d, J = 4.0 Hz), 4.57 (1H, s), 6.86 (1H, d, J = 8.4 Hz), 6.92 (1H, d, J =
8.4 Hz), 6.95 (1H, s) ppm. 13C NMR (100 MHz, CDCl3): 14.03, 22.58, 28.05, 32.10, 38.81,
56.02, 65.34, 73.76, 74.14, 112.09, 115.40, 119.69, 137.83, 146.35, 150.24 ppm. HRMS (ESI
+): calcd for C17H27O4 – H2O, 277.1804; found, 277.1795.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]pentan-1-ol (4l)
Yellow oil. Yield: 41%. 1H NMR (400 MHz, CDCl3): 0.88 (3H, t, J = 6.4 Hz), 1.22–1.35 (4H,
m), 1.65–1.77 (2H, m), 1.86 (1H, s), 2.18 (2H, d, J = 5.6 Hz), 3.84 (2H, s), 3.89–3.92 (1H, m),
4.00 (3H, s), 4.58 (1H, s), 4.96 (1H, s), 6.84–6.91 (3H, m) ppm. 13C NMR (100 MHz,
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CDCl3): 14.03, 22.59, 28.03, 33.04, 38.80, 56.05, 67.19, 72.98, 74.26, 78.83, 112.02, 113.65,
119.35, 137.76, 146.83, 149.62 ppm. HRMS (ESI+): calcd for C16H25O4 – H2O, 263.1647;
found, 263.1643.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]butan-1-ol (4m)
Yield: 40%. 1H NMR (400 MHz, CDCl3): 0.92 (3H, t, J = 7.2 Hz), 1.30 (1H, dd, J = 6.4, 9.6
Hz), 1.42 (1H, d, J = 7.2 Hz), 1.63 (1H, s), 1.81 (2H, bs), 2.19 (2H, m), 3.84 (2H, s), 3.90 (2H,
s), 4.00 (3H, s), 4.60 (1H, s), 4.97 (1H, s), 6.89 (3H, m) ppm. 13C NMR (100 MHz, CDCl3):
13.97, 19.08, 33.07, 41.24, 56.08, 67.22, 73.01, 74.07, 78.88, 112.05, 113.66, 119.33, 137.68,
146.89, 149.70 ppm. HRMS (ESI+): calcd for C15H23O4 – H2O, 249.1491; found, 249.1480.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-4-phenylbutan-1-ol (4n)
Yield: 20%. 1H NMR (400 MHz, CDCl3): 1.60 (1H, m), 1.74 (2H, m), 1.85 (2H, m), 2.18 (2H,
m), 2.64 (2H,t, J = 6.4 Hz), 3.83 (3H, s), 3.90 (2H, m), 4.04 (3H, s), 4.60 (1H, m), 4.95 (1H,
m), 6.83 (1H, d, J = 2 Hz), 6.84 (1H, s), 6.87–6.89 (1H, dd, J = 1.6, 1.6 Hz), 7.15 (3H, m), 7.25
(2H, d, J = 6.8 Hz) ppm. 13C NMR (100 MHz, CDCl3): 27.61, 33.07, 35.72, 38.51, 56.06,
67.22, 73.02, 74.17, 78.84, 112.01, 113.49, 119.36, 125.77, 128.30, 128.42, 137.39, 142.22,
146.92,149.73 ppm. HRMS (ESI+): calcd for C21H27O4 – H2O, 325.1804; found, 325.1792.
3-Cyclohexyl-1-[4-methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]propan-1-ol (4o)
Yield: 70%. 1H NMR (400 MHz, CDCl3): 0.86 (2H, t, J = 12 Hz), 1.09–1.30 (7H, m), 1.61–
1.69 (6H, m), 1.74–1.77 (2H, m), 2.16–2.20 (2H, m), 3.84 (3H, d, J = 2.8 Hz), 3.88–3.91 (1H,
m), 4.54 (1H, d, J = 6.8 Hz), 4.96 (1H, s), 6.83–6.85 (2H, dd, J = 2.8,5.2 Hz), 6.70 (1H, d, J =
7.6 Hz) ppm. 13C NMR (100 MHz, CDCl3): 26.36, 26.65, 33.06, 33.35, 33.53, 36.43, 37.64,
56.06, 67.22, 73.01, 74.67, 78.84, 112.00, 113.60, 119.37, 137.67, 146.85, 149.66 ppm. HRMS
(ESI+): calcd for C20H31O4 – H2O, 317.2117; found, 317.2112. Anal. Calcd for C20H30O4:
C, 71.82; H, 9.04. Found: C, 71.92; H, 9.10.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]--phenylpropan-1-ol (4p)
Yield: 99%. 1H NMR (400 MHz, CDCl3): 1.96–2.00 (1H, m), 2.09 (1H, s), 2.11–2.18 (2H,
m), 2.63–2.72 (2H, m), 3.83 (3H, s), 3.82 (3H, m), 3.85–3.90 (1H, m), 3.94–4.03 (3H, m), 4.59
(1H, t, J = 7.2 Hz), 4.93–4.95 (1H, m), 6.83 (1H, s), 6.85 (1H,s), 6.91 (1H, d, J = 8.4 Hz), 7.17
(3H, t, J = 4.4 Hz), 7.25–7.00 (2H, dd, J = 7.2, 7.6 Hz) ppm. 13C NMR (100 MHz, CDCl3):
32.14, 33.07, 40.49, 56.07, 67.22, 73.00, 73.49, 78.86, 112.08, 113.63, 119.41, 125.89, 128.42,
128.44, 137.35, 141.79, 146.92, 149.76 ppm. HRMS (ESI+): calcd for C20H25O4 – H2O,
311.1647; found, 311.1639. Anal. Calcd for C20H24O4, C, 73.15; H, 7.37; found, C, 73.25; H,
7.56.
2-Cyclohexyl-1-[4-methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]ethanol (4q)
Yield: 55%. 1H NMR (400 MHz, CDCl3): 0.94 (2H, m), 1.20 (2H, m), 1.36 (1H, m), 1.48 (1H,
m), 1.69 (7H, m), 2.18 (2H, m), 3.84 (3H, s), 3.90 (1H, m), 4.00 (2H, m), 4.71 (1H, s), 4.96
(1H, s), 6.83 (1H, s), 6.85 (1H, s), 6.92–6.89 (1H, q, J = 2.0, 6.0 Hz) ppm. 13C NMR (100
MHz, CDCl3): 26.17, 26., 26.56, 33.03, 33.07, 33.91, 34., 46.97, 56.07, 67.23, 71.79, 73.01,
78.86, 112.06, 113.59, 113.63, 119.27, 138.03, 146.88, 149.68 ppm. HRMS (ESI+): calcd for
C19H28O4 – H2O, 303.1960; found, 303.1975.
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-ylxoy)phenyl]-2,2-dimethylpropan-1-ol (4r)
Yield: 8.6%. 1H NMR (400 MHz, CDCl3): 0.92 (9H, d, J = 0.8 Hz), 1.95 (1H, s), 2.16–2.20
(2H, m), 3.90–3.92 (1H, m), 3.98–4.00 (3H, m), 4.36 (1H, s), 4.96 (1H, d, J = 2.0 Hz), 6.52
(1H, (d) t, J = 75.2 Hz), 6.85–6.87 (1H, dd, J = 2.0, 6.0 Hz), 6.89–6.91 (1H, dd, J = 2.0, 2.4
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Hz), 7.11 (1H, d, J = 8.0 Hz) ppm. 13C NMR (100 MHz, CDCl3): 25.88, 0.71, 32.98, 33.02,
35.71, 67.16, 72.80, 72.83, 78.72, 81.73, 114.69 (t, J = 160 Hz), 120.96, 121.93, 140.05, 140.88,
148.17 ppm. MS (EI+): calcd for C16H22F2O4, 316; found, 316.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-3-methyl-butan-1-ol (4s)
Yield: 34%. 1H NMR (400 MHz, CDCl3): 0.91–0.94 (6H, q, J = 4.4, 2.0 Hz), 1.24 (1H, s),
1.44–1.49 (1H, m), 1.64–1.72 (2H, m), 1.92 (1H, bs, O–H), 2.16–2.19 (2H, m), 3.83 (3H, s),
3.86–3.91 (1H, m), 3.97–4.02 (3H, m), 4.64–4.67 (1H, q, J = 5.6, 2.0 Hz), 4.94–4.97 (1H, m),
6.84 (1H, d, J = 8.4 Hz), 6.86 (1H, J = 2 Hz), 6.91–6.89 (1H, dd, J = 2, 6.4 Hz) ppm. 13C NMR
(100 MHz, CDCl3): 22.34, 23.09, 24.84, 33.04, 48.28, 56.06, 67.21, 72.41, 72.99, 78.85,
112.04, 113.62, 119.32, 137.96, 146.89, 149.68 ppm. HRMS (ESI+): calcd for C16H22O3 –
H2O, 263.1647; found, 263.1648.
3-[2-Difluoromethoxy-5-(1-hydroxypentyl)phenoxy]pyrrolidine-1-carboxylic Acid tert-Butyl
Ester (4t)
Yield: 25%. 1H NMR (400 MHz, CDCl3): 0.89 (3H, t, J = 6.8 Hz), 1.36 (4H, m), 1.46 (9H, s),
1.73 (2H, m), 1.95 (1H, d, J = 2.8 Hz), 2.20 (2H, m), 3.67 (4H, m), 4.63 (1H, s), 4.93 (1H, s),
6.65 (1H, t, J = 75.2 Hz), 6.91 (1H, s), 6.96 (1H, d, J = 1.6 Hz), 7.12 (1H, d, J = 6.8 Hz)
ppm. 13C NMR (100 MHz, CDCl3): 14.0, 22.55, 27.9, 28.47, 0.72, 30.82, 31.67, 39.02, 44.07,
51.08, 51.57, 74.02, 78.11, 79.61, 113.4, 119.4, 122.89 ppm. HRMS (ESI+): calcd for
C21H31F2NO5, 416.2248; found, 416.2247.
3[2-Difluoromethoxy-5-(1-hydroxy-3-methylbutyl)phenoxy]-pyrrolidine-1-carboxylic Acid
tert-Butyl Ester (4u)
Yield: 14%. 1H NMR (400 MHz, CDCl3): 0.96 (6H, d, J = 6.4 Hz), 1.46 (9H, s), 1.69 (2H, m),
1.90 (1H, d, J = 2.8 Hz), 2.20 (2H, m), 3.57 (4H, m), 4.71 (1H, s), 4.94 (1H, s), 6.65 (1H, d
(t), J = 75.2 Hz), 6.92 (1H, d, J = 6.8 Hz), 6.97 (1H, d, J = 1.2 Hz), 7.12 (1H, d, J = 6.4 Hz)
ppm. 13C NMR (100 MHz, CDCl3): 14.1 (d), 22.6, 24.7, 28.4, 31.5, 43.6 (d), 48.5, 51.5 (d),
60.3, 72.1, 79.60, 113.5 (d, J = 14 Hz), 119.4, 122.9, 140.3 ppm. HRMS (ESI+): calcd for
C17H21F2NO4 – (H2O + tert-butyl), 342.1515; found, 342.1159.
4-[5-(1-Hydroxypentyl)-2-methoxyphenoxy]piperidine-1-carboxylic Acid tert-Butyl Ester (4v)
Yield: 84%. 1H NMR (400 MHz, CDCl3): 0.95 (3H, t, J = 7.2 Hz), 1.44 (2H, q, J = 7.2, 7.6
Hz), 1.47 (9H, s), 1.69 (4H, m), 1.73 (2H, s), 1.92–1.96 (2H, m), 2.91 (2H, t, J = 7.2 Hz), 3.23–
3.00 (2H, m), 3.80 (2H, m), 4.63 (1H, s), 3.91 (3H, s), 4.50–4.51 (1H, m), 4.70–4.72 (1H, s),
6.92 (1H, d, J = 8.4 Hz), 7.57 (1H, d, J = 2 Hz), 7.60–7.63 (1H, dd, J = 2, 6.4 Hz) ppm. 13C
NMR (100 MHz, CDCl3): 14.03, 22.59, 28.06, 28.45, 30.83, 38.79, 56.04, 74.28, 74.53, 79.52,
112.13, 115.49, 119.75, 137.72, 146.47, 150.37, 154.84 ppm. HRMS (ESI+): calcd for
C18H25NO4 – (H2O + tert-butyl): 320.1862; found, 320.1882.
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-3-methylbutan-1-ol (4w)
Yield: 15%. 1H NMR (CDCl3): 7.13 (1H, d, J = 8.4 Hz), 6.95 (1H, s), 6.90 (1H, d, J = 8.4 Hz),
6.51 (1H, t, J = 75.2 Hz), 5.00 (1H, m), 4.72 (1H, m), 4.03–3.90 (4H, m), 2.20 (2H, m), 1.94
(1H, s, br), 1.70 (2H, m), 1.47 (1H, m), 0.96 (6H, d, J = 6.0 Hz). 13C NMR (CDCl3): 149.0,
144.3, 140.1, 122.9, 118.9, 116.3 (triplet, J = 258 Hz), 112.8, 78.8, 72.8, 72.2, 67.1, 48.5, 33.0,
24.8, 23.1, 22.2. MS-EI: 316 (M+).
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-pentan-1-ol (4za)
Yield: %. 1H NMR (CDCl3): 7.13 (1H, d, J = 8.0 Hz), 6.94 (1H, s), 6.90 (1H, dd, J = 2.0 and
8.4 Hz), 6.52 (1H, t, J = 75.2 Hz), 5.00 (1H, m), 4.64 (1H, m), 4.03–3.91 (4H, m), 2.18 (2H,
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m), 1.98 (1H, s, br), 1.75 (1H, m), 1.67 (1H, m), 1.42–1.24 (4H, m), 0.90 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 149.0 (s), 143.8 (s), 140.1 (s), 122.9 (d), 119.0 (d), 116.3 (triplet, J
= 258 Hz, d), 112.8 (d), 78.7 (d), 74.0 (d), 72.8 (t), 67.1 (t), 39.0 (t), 33.0 (t), 27.8 (t), 22.5 (t),
14.0 (q). MS-EI: 316 (M+).
3-Cyclohexyl-1-[4-difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]propan-1-ol (4zb)
Yield: 51%. 1H NMR (CDCl3): 7.11 (1H, d, J = 8.0 Hz), 6.94 (1H, s), 6.89 (1H, d, J = 8.4 Hz),
6.50 (1H, t, J = 74.8 Hz), 4.97 (1H, m), 4.59 (1H, m), 4.01–3.87 (4H, m), 2.18 (2H, m), 1.94
(1H, s, br), 1.80–1.67 (7H, m), 1.34–1.12 (6H, m), 0.88 (2H, m). 13C NMR (CDCl3): 149.1,
143.9, 140.4, 122.8, 119.2, 116.4 (triplet, J = 258 Hz), 113.4, 79.1, 74.4, 72.8, 67.1, 37.7, 36.7,
33.4, 33.3, 33.1, 26.6, 26.3.
2-Cyclohexyl-1-[4-difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]ethanol (4zc)
Yield: 35%. 1H NMR (CDCl3): 7.14 (1H, d, J = 8.4 Hz), 6.95 (1H, d, J = 2.0 Hz), 6.91 (1H,
dd, J = 2.0 and 8.0 Hz), 6.53 (1H, t, J = 75.2 Hz), 5.01 (1H, m), 4.77 (1H, m), 4.03–3.91 (4H,
m), 2.20 (2H, m), 2.00 (1H, s, br), 1.83–1.66 (6H, m), 1.52–1.39 (2H, m), 1.31–1.15 (3H, m),
0.98 (2H, m). 13C NMR (CDCl3): 149.0 (s), 144.3 (s), 140.0 (s), 122.9 (d), 118.91 (d), 118.89
(d), 116.3 (triplet, J = 258 Hz, d), 112.8 (d), 78.7 (d), 72.8 (t), 71.5 (d), 67.1 (t), 47.2 (t), 34.2
(d), 33.9 (t), 33.0 (t), 32.8 (t), 26.5 (t), 26.2 (t), 26.1 (t).
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-3-phenylpropan-1-ol (4zd)
Yield: 46%. 1H NMR (CDCl3): 7.30–7.25 (2H, m), 7.20–7.11 (4H, m), 6.92–6.88 (2H, m),
6.50 (1H, t, J = 74.8 Hz), 4.96 (1H, m), 4.64 (1H, m), 3.99–3.89 (4H, m), 2.72 (2H, m), 2.18–
1.97 (5H, m). 13C NMR (CDCl3): 149.0 (s), 143.5 (s), 141.4 (s), 140.1 (s), 128.42 (d), 128.36
(d), 126.0 (d), 122.9 (d), 119.0 (d), 116.2 (triplet, J = 258 Hz, d), 112.81 (d), 112.78 (d), 78.7
(d), 73.2 (d), 72.7 (t), 67.1 (t), 40.6 (t), 32.9 (t), 31.9 (t).
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-4-phenylbutan-1-ol (4ze)
Yield: 56%. 1H NMR (CDCl3): 7.28–7.25 (2H, m), 7.19–7.10 (4H, m), 6.89–6.85 (2H, m),
6.50 (1H, t, J = 75.2 Hz), 4.95 (1H, m), 4.64 (1H, m), 3.99–3.89 (4H, m), 2.63 (2H, t, J = 6.8
Hz), 2.15 (2H, m), 2.01 (1H, s, br), 1.78–1.61 (4H, m). 13C NMR (CDCl3): 149.0 (s), 143.6
(s), 142.0 (s), 140.1 (s), 128.37 (d), 128.31 (d), 125.8(d), 122.9 (d), 119.0 (d), 116.2 (triplet,
J = 258 Hz, d), 112.7 (d), 78.7 (d), 73.8 (d), 72.8 (t), 67.1 (t), 38.6 (t), 35.6 (t), 33.0 (t), 27.4
(t).
1-(3-Cyclopentyloxy-4-difluoromethoxyphenyl)-3-methyl-butan-1-ol (4zf)
Yield: 34%. 1H NMR (CDCl3): 7.09 (1H, d, J = 8.4 Hz), 6.97 (1H, d, J = 1.6 Hz), 6.83 (1H,
dd, J = 1.6 and 8.4 Hz), 6.51 (1H, t, J = 75.6 Hz), 4.82 (1H, m), 4.70 (1H, m), 1.92–1.79 (7H,
m), 1.72–1.62 (4H, m), 1.46 (1H, m), 0.95 (6H, d, J = 6.0 Hz). 13C NMR (CDCl3): 149.6 (s),
144.0 (s), 140.0 (triplet, J = 3.0 Hz, s), 122.7 (d), 117.9 (d), 116.4 (triplet, J = 257 Hz, d), 112.6
(d), 80.5 (d), 72.4 (d), 48.4 (t), 32.74 (t), 32.73 (t), 24.8 (d), 23.8 (t), 23.1 (q), 22.2 (q).
4-[2-Difluoromethoxy-5-(1-hydroxypentyl)phenoxy]piperidine-1-carboxylic Acid tert-Butyl
Ester (4zg)
Yield: 57%. 1H NMR (CDCl3): 7.12 (1H, d, J = 8.0 Hz), 7.02 (1H, d, J = 1.2 Hz), 6.90 (1H,
dd, J = 1.6 and 8.0 Hz), 6.51 (1H, t, J = 74.8 Hz), 4.63 (1H, m), 4.52 (1H, m), 3.67 (2H, m),
3.41 (2H, m), 2.11 (1H, s, br), 1.90 (2H, m), 1.80–1.63 (4H, m), 1.47 (9H, s), 1.42–1.28 (4H,
m), 0.88 (3H, t, J = 7.2 Hz).
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Yield: 35%. 1H NMR (CDCl3): 7.13 (1H, d, J = 8.4 Hz), 7.02 (1H, s), 6.90 (1H, d, J = 8.0 Hz),
6.54 (1H, t, J = 75.2 Hz), 4.64 (1H, m), 4.52 (1H, m), 3.97 (2H, m), 3.56 (2H, m), 2.02 (3H,
m), 1.82–1.61 (4H, m), 1.44 (1H, m), 1.33 (1H, m), 0.94 (3H, t, J = 7.2 Hz). 13C NMR
(CDCl3): 148.8 (s), 143.9 (s), 140.7 (s), 122.8 (d), 119.2 (d), 116.4 (triplet, J = 258 Hz, d),
114.2 (d), 73.8 (d), 73.3 (d), 64.8 (t), 41.4 (t), 31.7 (t), 18.9 (t), 13.9 (q). MS-EI: 316 (M+).
1-[4-Difluoromethoxy-3-(pyridin-2-yloxy)phenyl]>butan-1-ol (4zi)
Yield: 52%. 1H NMR (CDCl3): 8.07 (1H, m), 7.70 (1H, m), 7.26–7.15 (3H, m), 7.00–6.96 (2H,
m), 6.40 (1H, t, J = 74.4 Hz), 4.64 (1H, m), 2.33 (1H, s, br), 1.70–1.60 (2H, m), 1.48–1.26 (2H,
m), 0.92 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 163.0 (s), 147.3 (d), 145.0 (s), 144.1 (s), 142.4
(s), 139.6 (d), 123.2 (d), 121.9 (d), 121.3 (d), 118.7 (d), 116.3 (triplet, J = 258 Hz, d), 111.2
(d), 73.3 (d), 41.1 (t), 18.9 (t), 13.9 (q).
1-(3,4-Bisdifluoromethoxyphenyl]-4-phenylbutan-1-ol (4zj)
Yield: 43%. 1H NMR (CDCl3): 7.00–7.14 (8H, m), 6.52 (1H, t, J = 73.6 Hz), 6.50 (1H, t, J =
73.6 Hz), 4.68 (1H, m), 2.64 (2H, t, J = 7.2 Hz), 2.11 (1H, s, br), 1.92–1.58 (4H, m).
1-(3,4-Bisdifluoromethoxyphenyl]pentan-1-ol (4zk)
Yield: 25%. 1H NMR (CDCl3): 7.24–7.18 (3H, m), 6.53 (1H, t, J = 73.6 Hz), 6.51 (1H, t, J =
73.6 Hz), 4.67 (1H, m), 1.92 (1H, s, br), 1.77–1.67 (2H, m), 1.40–1.23 (4H, m), 0.89 (3H, t,
J = 7.2 Hz). 13C NMR (CDCl3): 144.1 (s), 142.3 (s), 141.2 (s), 123.9 (d), 122.3 (d), 119.8 (d),
115.8 (triplet, J = 261 Hz, d), 73.5 (d), 38.9 (t), 27.8 (t), 22.5 (t), 13.9 (q).
1-(3,4-Bisdifluoromethoxyphenyl]butan-1-ol (4zl)
Yield: 80%. 1H NMR (CDCl3): 7.24–7.17 (3H, m), 6.53 (1H, t, J = 73.6 Hz), 6.51 (1H, t, J =
73.6 Hz), 4.66 (1H, t, J = 6.4 Hz), 2.19 (1H, s, br), 1.74–1.60 (2H, m), 1.43–1.30 (2H, m), 0.93
(3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 144.1 (s), 142.3 (s), 141.2 (s), 123.9 (d), 122.2 (d),
119.7 (d), 115.8 (triplet, J = 260 Hz, d), 73.2 (d), 41.3 (t), 18.8 (t), 13.7 (q). MS-EI: 282
(M+).
1-(3,4-Bisdifluoromethoxyphenyl]-3-phenylpropan-1-ol (4zm)
Yield: 73%. 1H NMR (CDCl3): 7.30–7.17 (8H, m), 6.51 (1H, t, J = 74.0 Hz), 6.50 (1H, t, J =
73.6 Hz), 4.67 (1H, m), 2.71 (2H, m), 2.18–1.98 (3H, m). 13C NMR (CDCl3): 143.8, 142.3,
141.2, 128.9, 128.5, 128.4, 126.0, 123.9, 122.3, 119.8, 115.8 (triplet, J = 260 Hz), 72.6, 40.5,
31.8.
1-(3,4-Bisdifluoromethoxyphenyl]-2-cyclohexylethanol (4zn)
1H NMR (CDCl3): 7.24–7.17 (3H, m), 6.53 (1H, triplet, J = 74.0 Hz), 6.51 (1H, triplet, J =
74.0 Hz), 4.76 (1H, m), 2.01 (1H, s, br), 1.82–1.62 (6H, m), 1.44 (2H, m), 1.26–1.14 (3H, m),
0.94 (2H, m). 13C NMR (CDCl3): 144.6, 142.3, 141.2, 123.8, 122.3, 119.7, 115.8 (triplet, J =
260 Hz), 71.0, 47.2, 34.1, 33.9, 32.7, 26.5, 26.2, 26.1.
General Procedure for the Synthesis of 5 by Oxidization of the Alcohols with PCC
To a solution of the alcohol 4 (1 mmol) in dichloromethane (5 mL) was added PCC in portions.
The resulting mixture was stirred at room temperature for 2 h. The solvent was removed in
vacuo and the residue was purified by flash chromatography to afford 5.
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4-(2-Methoxy-4-pentanoylphenoxy)piperidine-1-carboxylic Acid tert-Butyl Ester (5a)
Yellow solid, mp 41–43 °C. Yield: 18%. 1H NMR (CDCl3): 7.55–7.53 (2H, m), 6.92 (1H, d,
J = 8.8 Hz), 4.56 (1H, m), 3.90 (3H, s), 3.78 (2H, m), 3.30 (2H, m), 2.92 (2H, t, J = 7.2 Hz),
1.95 (2H, m), 1.81 (2H, m), 1.70 (2H, m), 1.47 (9H, s), 1.40 (2H, m), 0.95 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 199.2 (s), 154.7 (s), 150.8 (s), 150.4 (s), 130.9 (s), 122.2 (d), 114.4
(d), 111.2 (d), 79.6 (s), 73.9 (d), 56.0 (q), 40.6 (t), 37.8 (t), 30.5 (t), 28.4 (q), 26.8(t), 22.5 (t),
14.0 (q). MS-EI: 391 (M+).
4-(4-Butyryl-2-methoxyphenoxy)piperidine-1-carboxylic Acid tert-Butyl Ester (5b)
Yield: 40%. 1H NMR (CDCl3): 7.55–7.53 (2H, m), 6.93 (1H, d, J = 8.8 Hz), 4.56 (1H, m),
3.90 (3H, s), 3.77 (2H, m), 3.30 (2H, m), 2.92 (2H, t, J = 7.6 Hz), 1.94 (2H, m), 1.85–1.74 (4H,
m), 1.47 (9H, s), 1.00 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 198.8 (s), 154.6 (s), 150.7 (s),
150.3 (s), 130.9 (s), 122.2 (d), 114.4 (d), 111.1 (d), 79.5 (s), 73.8 (d), 55.9 (q), 40.6 (t), 39.9
(t), 30.4 (t), 28.3 (q), 17.9 (t), 13.8 (q). MS-EI: 377 (M+).
1-[3-Methoxy-4-(tetrahydropyran-4-yloxy)phenyl]butan-1-one (5c)
Yellow solid, mp 60–62 °C. Yield: 93%. 1H NMR (CDCl3): 7.55–7.53 (2H, m), 6.93 (1H, d,
J = 8.0 Hz), 4.57 (1H, m), 4.02 (2H, m), 3.92 (3H, s), 3.58 (2H, m), 2.90 (2H, t, J = 7.2 Hz),
2.04 (2H, m), 1.88 (2H, m), 1.77 (2H, m), 1.00 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 199.0
(s), 150.7 (s), 150.3 (s), 130.8 (s), 122.2 (d), 114.2 (d), 111.2 (d), 73.2 (d), 65.1 (t), 56.0 (q),
40.0 (t), 31.9 (t), 18.0 (t), 13.9 (q). MS-EI: 278 (M+).
1-[3-Methoxy-4-(tetrahydropyran-4-yloxy)phenyl]pentan-1-one (5d)
Yield: 99%. 1H NMR (CDCl3): 7.55–7.54 (2H, m), 6.93 (1H, d, J = 8.0 Hz), 4.58 (1H, m),
4.02 (2H, m), 3.91 (3H, s), 3.57 (2H, m), 2.92 (2H, t, J = 7.2 Hz), 2.05 (2H, m), 1.87 (2H, m),
1.71 (2H, m), 1.42 (2H, m), 0.95 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 199.0 (s), 150.7 (s),
150.2 (s), 130.8 (s), 122.2 (d), 114.2 (d), 111.1 (d), 73.2 (d), 65.1 (t), 55.9 (q), 37.8 (t), 31.7
(t), 26.7 (t), 22.4 (t), 13.8 (q). MS-EI: 2 (M+).
1-[3-Methoxy-4-(tetrahydrofuran-3-yloxy)phenyl]butan-1-one (5e)
Yield: 75%. 1H NMR (CDCl3): 7.56–7.54 (2H, m), 6.83 (1H, d, J = 8.0 Hz), 5.02 (1H, m),
4.03–3.90 (7H, m), 2.90 (2H, t, J = 7.2 Hz), 2.22 (2H, m), 1.76 (2H, m), 1.00 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 198.7 (s), 150.9 (s), 149.6 (s), 130.6 (s), 122.1 (d), 112.9 (d), 110.7
(d), 78.4 (d), 72.6 (t), 66.9 (t), 55.7 (q), 39.8 (t), 32.8 (t), 17.8 (t), 13.7 (q). MS-EI: 264 (M+).
1-[3-Methoxy-4-(tetrahydrofuran-3-yloxy)phenyl]pentan-1-one (5f)
Yield: 55%. 1H NMR (CDCl3): 7.56–7.54 (2H, m), 6.83 (1H, d, J = 8.8 Hz), 5.02 (1H, m),
4.03–3.90 (7H, m), 2.92 (2H, t, J = 7.2 Hz), 2.22 (2H, m), 1.71 (2H, m), 1.41 (2H, m), 0.95
(3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 199.1 (s), 151.0 (s), 149.8 (s), 130.7 (s), 122.2 (d),
113.0 (d), 111.0 (d), 78.5 (d), 72.8 (t), 67.1 (t), 55.9 (q), 37.8 (t), 33.0 (t), 26.7 (t), 22.4 (t), 13.8
(q). MS-EI: 278 (M+).
1-[3-Methoxy-4-(pyridine-2-yloxy)phenyl]pentan-1-one (5g)
Yield: 60%. 1H NMR (CDCl3): 8.13 (1H, dd, J = 2.0 and 5.2 Hz), 7.70 (1H, m), 7.66 (1H, d,
J = 2.0 Hz), 7.61 (1H, dd, J = 2.0 and 8.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 7.00–6.98 (2H, m),
3.82 (3H, s), 2.96 (2H, t, J = 7.2 Hz), 1.77 (2H, m), 1.42 (2H, m), 0.96 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 199.3 (s), 163.1 (s), 151.8 (s), 147.4 (d), 146.7 (s), 139.4 (d), 134.7
(s), 122.4 (d), 121.8 (d), 118.5 (d), 111.8 (d), 111.1 (d), 55.9 (q), 38.1 (t), 26.5 (t), 22.4 (t), 13.9
(q). MS-ESI (+): 286.24 [M + H]+.
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Yield: 88%. 1H NMR (CDCl3): 8.13 (1H, dd, J = 2.0 and 5.2 Hz), 7.70 (1H, m), 7.66 (1H, d,
J = 2.0 Hz), 7.61 (1H, dd, J = 2.0 and 8.0 Hz), 7.20 (1H, d, J = 8.0 Hz), 7.00–6.98 (2H, m),
3.82 (3H, s), 2.94 (2H, t, J = 7.2 Hz), 1.78 (2H, m), 1.01 (3H, t, J = 7.2 Hz). 13C NMR
(CDCl3): 199.1 (s), 163.1 (s), 151.8 (s), 147.4 (d), 146.7 (s), 139.4 (d), 134.7 (s), 122.4 (d),
121.8 (d), 118.5 (d), 111.8 (d), 111.1 (d), 55.9 (q), 40.3 (t), 17.8 (t), 13.9 (q). HRMS-ESI (+):
calcd for C16H18NO3, 272.1287; found, 272.1282 (M+).
1-[4-Methoxy-3-(piperidin-4-yloxy)phenyl]pentan-1-one (5i)
Yellow oil. Yield: 96%. 1H NMR (400 MHz, CDCl3): 0.93 (3H, t, J = 7.2 Hz), 1.36–1.43 (2H,
m), 2.15 (4H, d, J = 3.6 Hz), 2.91 (2H, t, J = 7.6 Hz), 3.33 (2H, d, J = 12 Hz), 3.53 (2H, s),
3.91 (3H, s), 4.66 (1H, t, J = 3.2 Hz), 6.95 (1H, d, J = 8.4 Hz), 7.56 (1H, d, J = 2 Hz), 7.66–
7.69 (1H, dd, J = 2, 6.4 Hz) ppm. 13C NMR (100 MHz, CDCl3): 13.82, 22.43, 26.97 (d), 37.96,
40.48, 55.91, 70.00, 111.28, 113.98, 116.83, 117.24, 125.08, 1.99, 145.59, 155.60, 161.00 (d),
200.65 ppm. HRMS (ESI+): calcd for C17H26NO3, 2.1913; found, 2.1900.
4-Methoxy-3-(tetrahydropyran-4-yloxyphenyl]quinolin-3-ylmethanone (5j)
White solid, mp 72–74 °C. Yield: 88%. 1H NMR (400 MHz, CDCl3): 1.85–1.92 (2H, m), 2.04–
2.10 (2H, m), 3.53–3.59 (2H, m), 3.97 (3H, s), 4.02 (2H, t, J = 6.0 Hz), 4.00–4.05 (2H, m),
4.56 (1H, m), 6.97 (2H, d, J = 8.4 Hz), 7.45–7.47 (1H, dd, J = 2.0, 6.4 Hz), 7.58 (1H, d, J =
1.6 Hz), 7.65 (1H, t, J = 7.2 Hz), 7.86 (1H, t, J = 6.8 Hz), 8.21 (1H, d, J = 8.4 Hz), 8.54 (1H,
d, J = 2.0 Hz), 9.27 (1H, d, J = 2.0 Hz) ppm. 13C NMR (100 MHz, CDCl3): 0.72, 31.95, 56.19,
65.34, 73.75, 110.89, 117.15, 126.71, 127.60, 1.02, 1.51, 131.65, 138.27, 146.75, 150.27 ppm.
MS (ESI+): calcd for C22H21NO4, 363.1; found, 363.
1-[4-Methoxy-3-(tetrahydropyran-4-yloxy)phenyl]butan-1-one (5k)
Yellow oil. Yield: 63%. 1H NMR (400 MHz, CDCl3): 1.02 (3H, t, J = 7.2 Hz), 1.78–1.73 (2H,
q, J = 7.6, 6.4 Hz), 1.85 (2H, m), 2.05 (2H, d, J = 10.8 Hz), 2.89 (2H, t, J = 7.2 Hz), 3.55 (2H,
t, J = 10 Hz), 3.92 (3H, s), 4.02 (2H, t, J = 6.0 Hz), 4.51 (1H, s), 6.91 (1H, d, J = 8.0 Hz), 7.57
(1H, s), 7.62 (1H, d, J = 8.4 Hz) ppm. 13C NMR (100 MHz, CDCl3): 13.95, 18.10, 32.00,
40.08, 56.07, 65.41, 73.70, 110.87, 115.63, 123.46, 130.33, 146.44, 154.84, 199.14 ppm.
HRMS (ESI+): calcd for C16H22O4, 279.1596; found, 279.1606.
1-[4-Methoxy-3-(tetrahydropyran-4-yloxy)phenyl]pentan-1-one (5l)
Yield: 75%. 1H NMR (400 MHz, CDCl3): 0.95 (3H, t, J = 7.2 Hz), 1.41 (2H, q, J = 7.2, 7.2
Hz), 1.72 (2H, q, J = 7.2, 7.2 Hz), 1.84 (2H, t, J = 4.4 Hz), 2.05 (2H, d, J = 10.0 Hz), 2.90 (2H,
t, J = 7.2 Hz), 3.55 (2H, t, J = 9.2 Hz), 3.92 (3H, s), 4.03 (2H, d, J = 11.2 Hz), 4.52 (1H, s),
6.91 (1H, d, J = 8.0 Hz), 7.57 (1H, s), 7.62 (1H, d, J = 8.4 Hz) ppm. 13C NMR (100 MHz,
CDCl3): 13.95, 22.52, 26.83, 31.99, 37.86, 56.04, 65.37, 73.68, 110.87, 115.67, 123.48, 130.27,
146.42, 154.83, 199.14 ppm. HRMS (ESI+): calcd for C17H25O4, 3.1753; found, 3.1754. Anal.
Calcd for C17H24O4 · 1/8H2O: C, 69.24; H, 8.23. Found: C, 69.27; H, 8.61.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]pentan-1-one (5m)
Yield: 92%. 1H NMR (400 MHz, CDCl3): 0.95 (3H, t, J = 7.2 Hz), 1.43 (2H, q, J = 6.8, 7.2
Hz), 1.72 (2H, t, J = 6.8 Hz), 2.24 (2H, m), 2.91 (2H, t, J = 6.8 Hz), 3.92 (4H, s), 4.03 (3H, s),
5.03 (1H, s), 6.90 (1H, d, J = 7.6 Hz), 7.48 (1H, s), 7.61 (1H, d, J = 8 Hz) ppm. 13C NMR (100
MHz, CDCl3): 13.96, 22.54, 26.84, 33.01, 37.86, 56.07, 67.23, 72.97, 78.74, 110.72, 113.90,
123.30, 130.22, 146.90, 154.24, 199.10 ppm. HRMS (ESI+): calcd for C16H23O4, 279.1596;
found, 279.1598.
Zheng et al. Page 17














Yield: 64%. 1H NMR (400 MHz, CDCl3): 1.00 (3H, t, J = 7.2 Hz), 1.75 (2H, m), 2.24 (2H,
m), 2.91 (2H, t, J = 7.2 Hz), 3.91 (4H, s), 4.06 (3H, s), 5.02 (1H, s), 6.91 (1H, d, J = 8.4 Hz),
7.48 (1H, s), 7.61 (1H, d, J = 8.4 Hz) ppm. 13C NMR (100 MHz, CDCl3): 13.98, 18.12, 33.03
(d), 40.08, 56.07, 67.25 (d), 72.99 (d), 78.77, 110.76 (d), 113.92, 123.31, 130.27 (d), 146.92,
154.28 (d), 198.95 ppm. HRMS (ESI+): calcd for C15H21O4, 265.1440; found, 265.1436.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-4-phenyl-butan-1-one (5o)
Yield: 80%. 1H NMR (400 MHz, CDCl3): 2.11(2H, d, J = 7.6 Hz), 2.24 (2H, d, J = 5.2 Hz),
2.76 (2H, t, J = 7.6 Hz), 2.96 (2H, t, J = 7.6 Hz), 3.94 (4H, s), 4.06 (3H, s), 6.92 (1H, d, J =
8.4 Hz), 7.26 (3H, d, J = 7.2 Hz), 7.30–7.35 (2H, q, J = 7.6, 4.8 Hz), 7.50 (1H, s), 7.60 (1H,
d, J = 8 Hz) ppm. 13C NMR (100 MHz, CDCl3): 26.08, 33.00, 35.27, 37.22, 56.08, 67.24,
72.97, 78.71, 110.72, 113.77, 123.27, 125.95, 128.40, 128.54, 130.11, 141.75, 146.90, 154.30,
198.63 ppm. HRMS (ESI+): calcd for C21H25O4, 341.1753; found, 341.1748.
3-Cyclohexyl-1-[4-methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]propan-1-one (5p)
Yield: 95%. 1H NMR (400 MHz, CDCl3): 0.88–0.97 (2H, q, J = 11.6, 10 Hz), 1.31 (4H, m),
1.76 (7H, m), 2.20 (2H, m), 2.90 (2H, t, J = 7.6 Hz), 3.90 (4H, s), 4.02 (3H, s), 5.01 (1H, s),
6.89 (1H, d, J = 8.4 Hz), 7.47 (1H, s), 7.60 (1H, d, J = 7.6 Hz) ppm. 13C NMR (100 MHz,
CDCl3): 26., 26.58, 32.18, 33.01, 33.23, 35.69, 37.48, 56.07, 67.24, 72.98, 78.72, 110.71,
113.89, 123., 130.16, 146.89, 154.22, 199.38 ppm. HRMS (ESI+): calcd for C20HO4,
333.2066; found, 333.2067. Anal. Calcd for C20H28O4: C, 72.26; H, 8.49. Found: C, 71.95;
H, 8.76.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-3-phenyl-propan-1-one (5q)
Yield: 98%. 1H NMR (400 MHz, CDCl3): 2.21 (2H, s), 3.06 (2H, s), 3.25 (2H, s), 3.91 (4H,
s), 4.02 (3H, s), 5.01 (1H, s), 6.89 (1H, d, J = 7.6 Hz), 7.21–7.30 (5H, m), 7.48 (1H, s), 7.60
(1H, d, J = 6.8 Hz) ppm. 13C NMR (100 MHz, CDCl3): 30.42, 33.00, 39.99, 56.08, 67.24,
72.96, 78.73, 110.74, 113.80, 123.27, 126.14, 128.45, 128.54, 1.98, 141.41, 146.93, 154.40,
197.72 ppm. HRMS (ESI+): calcd for C20H23O4, 327.1596; found, 327.1609. Anal. Calcd for
C20H22O4: C, 73.60; H, 6.79. Found: C, 73.57; H, 7.09.
2-Cyclohexyl-1-[4-methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]ethanone (5r)
Yellow oil. Yield: 78%. 1H NMR (400 MHz, CDCl3): 1.02 (2H, m), 1. (3H, m), 1.76 (5H, m),
1.96 (1H, m), 2.22 (2H, m), 2.76 (2H, d, J = 6.8 Hz), 3.91 (1H, s), 4.03 (3H, s), 5.02 (1H, s),
6.90 (1H, d, J = 8.4 Hz), 7.47 (1H, d, J = 2.0 Hz), 7.60 (1H, q, J = 2.0, 6.4 Hz) ppm. 13C NMR
(100 MHz, CDCl3): 26.18, 26.27, 33.01, 33.50, 34.96, 45.73, 56.08, 67.24, 72.99, 78.72,
110.68, 113.89, 123.45, 130.62, 146.88, 154.24, 198.76 ppm. HRMS (ESI+): calcd for
C19H26O4, 319.1909; found, 319.1911
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-2,2-dimethylpropan-1-one (5s)
Yellow oil. Yield: 81%. 1H NMR (400 MHz, CDCl3): 1.36 (9H, s), 2.19–2.25 (2H, m), 3.91–
3.95 (1H, m), 3.99–4.03 (3H, m), 5.00 (1H, s), 6.59 (1H, t, J = 74.8 Hz), 7.18 (1H, d, J = 8.4
Hz), 7.30 (1H, d, J = 2.0 Hz), 7.40–7.42 (1H, dd, J = 2.0, 1.6 Hz) ppm. 13C NMR (100 MHz,
CDCl3): 28.15, 28.71, 32.96, 44.22, 67.16, 72.81, 78.94, 115.84 (d, J = 36 Hz), 121.77 (d),
136.04, 148.72, 206.85 ppm. MS (EI+): calcd for C16H20F2O4, 314; found, 314.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-3-methyl-butan-1-one (5t)
Yield: 93%. 1H NMR (400 MHz, CDCl3): 0.99 (6H, d, J = 6.4 Hz), 2.19–2.28 (3H, m), 2.77
(3H, d, J = 6.8 Hz), 3.90 (4H, d, J = 4.8 Hz), 4.02 (3H, t, J = 3.6 Hz), 5.02 (1H, d, J = 3.2 Hz),
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6.89 (1H, d, J = 8.4 Hz), 7.47 (1H, d, J = 1.6 Hz), 7.57–7.59 (1H, dd, J = 2.0, 1.6 Hz)
ppm. 13C NMR (100 MHz, CDCl3): 22.82, 25.48, 0.70, 33.00, 47.01, 56.05, 67.23, 72.97,
78.72, 110.67, 113.87, 123.39, 130.54, 146.90, 154.24, 198.73 ppm. MS (EI+): calcd for
C16H22O4, 278; found, 278.
1-[4-Methoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-4-methyl-pentan-1-one (5u)
Yield: 93%. 1H NMR (400 MHz, CDCl3): 0.95 (6H, d, J = 6.0 Hz), 1.59–1.64 (3H, m), 2.19–
2.25 (2H, m), 2.90 (2H, t, J = 7.6 Hz), 3.88–3.94 (4H, m), 4.02–4.06 (3H, m), 5.01–5.03 (1H,
q, J = 2.4, 2.8 Hz), 6.91 (1H, d, J = 8.4 Hz), 7.48 (1H, d, J = 1.6 Hz), 7.59–7.62 (1H, dd, J =
6.8, 1.6 Hz) ppm. 13C NMR (100 MHz, CDCl3): 22.46, 27.90, 29.70, 33.00, 33.64, 36.16,
56.05, 67.22, 72.97, 78.72, 110.71, 113.88, 123., 130.15, 146.90, 154.23, 199.28 ppm. MS (EI
+): calcd for C17H24O4, 292; found, 292.
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-3-methylbutan-1-one (5v)
Yield: 65%. 1H NMR (CDCl3): 7.56–7.53 (2H, m), 7.23 (1H, d, J = 8.8 Hz), 6.62 (1H, t, J =
74.4 Hz), 5.06 (1H, m), 4.06–3.93 (4H, m), 2.80 (2H, d, J = 6.8 Hz), 2.32–2.18 (3H, m), 1.01
(6H, d, J = 6.8 Hz). 13C NMR (CDCl3): 198.6 (s), 149.0 (s), 144.5 (s), 135.5 (s), 122.2 (d),
122.0 (d), 115.7 (triplet, J = 259 Hz, d), 114.0 (d), 78.9 (d), 72.8 (t), 67.1 (t), 47.3 (t), 32.9 (t),
25.2 (s), 22.7 (q). MS-EI: 314 (M+).
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-3-pentan-1-one (5za)
Yield: 43%. 1H NMR (CDCl3): 7.57–7.55 (2H, m), 7.23 (1H, d, J = 8.0 Hz), 6.62 (1H, t, J =
74.4 Hz), 5.06 (1H, m), 4.03–3.92 (4H, m), 2.93 (2H, t, J = 7.2 Hz), 2.32–2.15 (2H, m), 1.71
(2H, m), 1.41 (2H, m), 0.96 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 199.0 (s), 149.0 (s), 144.5
(s), 135.2 (s), 122.08 (d), 122.05 (d), 115.7 (triplet, J = 260 Hz, d), 114.0 (d), 78.9 (d), 72.7
(t), 67.1 (t), 38.2 (t), 32.9 (t), 26.5 (t), 22.4 (t), 13.9 (q). MS-EI: 314 (M+).
Cyclohexyl-1-[4-difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]propan-1-one (5zb)
Yield: 83%. 1H NMR (CDCl3): 7.57–7.54 (2H, m), 7.23 (1H, d, J = 8.0 Hz), 6.62 (1H, t, J =
74.4 Hz), 5.06 (1H, m), 4.03–3.92 (4H, m), 2.94 (2H, t, J = 7.6 Hz), 2.28–2.18 (2H, m), 1.76–
1.59 (7H, m), 1.31–1.16 (4H, m), 0.97 (2H, m). 13C NMR (CDCl3): 199.3 (s), 149.0 (s), 144.5
(s), 135.2 (s), 122.1 (d), 115.7 (triplet, J = 258 Hz, d), 114.0 (d), 78.9 (d), 72.7 (t), 67.1 (t),
37.4 (d), 36.0 (t), 33.2 (t), 32.9 (t), 31.8 (t), 26.5 (t), 26.3 (t). MS-EI: 368 (M+).
2-Cyclohexyl-1-[4-difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]ethanone (5zc)
Yield: 89%. 1H NMR (CDCl3): 7.56–7.53 (2H, m), 7.23 (1H, d, J = 8.8 Hz), 6.62 (1H, t, J =
74.4 Hz), 5.06 (1H, m), 4.06–3.90 (4H, m), 2.79 (2H, d, J = 6.8 Hz), 2.30–2.18 (2H, m), 1.96
(1H, m), 1.77–1.65 (5H, m), 1.31–1.15 (4H, m), 1.03 (2H, m). 13C NMR (CDCl3): 198.7 (s),
149.0 (s), 144.5 (s), 135.6 (s), 122.2 (d), 122.0 (d), 115.7 (triplet, J = 260 Hz, d), 114.0 (d),
78.9 (d), 72.8 (t), 67.1 (t), 46.0 (t), 34.7 (d), 33.4 (t), 32.9 (t), 26.2 (t), 26.1 (t). MS-EI: 354
(M+).
1-[4-Difluoromethoxy-3-(tetrahydrofuran-3-yloxy)phenyl]-3-phenylpropan-1-one (5zd)
Yellow oil. Yield: 88%. 1H NMR (CDCl3): 7.55–7.52 (2H, m), 7.31–7.19 (6H, m), 6.61 (1H,
t, J = 74.4 Hz), 5.03 (1H, m), 4.03–3.89 (4H, m), 3.27 (2H, t, J = 7.6 Hz), 3.05 (2H, t, J = 7.6
Hz), 2.27–2.14 (2H, m). 13C NMR (CDCl3): 197.6 (s), 149.0 (s), 144.6 (s), 141.0 (s), 134.9
(s), 128.51 (d), 128.35 (d), 126.2 (d), 122.00 (d), 121.99 (d), 115.7 (triplet, J = 260 Hz, d),
113.9 (d), 78.8 (d), 72.7 (t), 67.1 (t), 40.2 (t), 32.9 (t), 30.1 (t). MS-EI: 362 (M+).
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Yellow oil. Yield: 91%. 1H NMR (CDCl3): 7.51–7.47 (2H, m), 7.31–7.26 (2H, m), 7.21–7.19
(4H, m), 6.61 (1H, t, J = 74.4 Hz), 5.03 (1H, m), 4.04–3.90 (4H, m), 2.94 (2H, t, J = 7.2 Hz),
2.72 (2H, t, J = 7.2 Hz), 2.28–2.14 (2H, m), 2.08 (2H, m). 13C NMR (CDCl3): 198.5 (s), 149.0
(s), 144.6 (s), 141.5 (s), 135.1 (s), 128.48 (d), 128.42 (d), 126.0 (d), 122.05 (d), 122.04 (d),
115.7 (triplet, J = 259 Hz, d), 113.9 (d), 78.8 (d), 72.7 (t), 67.1 (t), 37.5 (t), 35.1 (t), 32.9 (t),
25.7 (t). MS-EI: 376 (M+).
1-(3-Cyclopentyloxy-4-difluoromethoxyphenyl]-3-methyl-butan-1-one (5zf)
Yield: 74%. 1H NMR (CDCl3): 7.58 (1H, d, J = 4.0 Hz), 7.49 (1H, dd, J = 4.0 and 8.4 Hz),
7.19 (1H, d, J = 8.4 Hz), 6.63 (1H, t, J = 75.2 Hz), 4.90 (1H, m), 2.80 (2H, d, J = 6.8 Hz), 2.28
(1H, m), 1.97–1.79 (7H, m), 1.69–1.64 (2H, m), 1.00 (6H, d, J = 6.8 Hz). 13C NMR (CDCl3):
198.9 (s), 149.6 (s), 144.4 (s), 135.5 (s), 122.0 (d), 121.3 (d), 115.8 (triplet, J = 259 Hz, d),
114.1 (d), 80.8 (d), 47.3 (t), 32.7 (t), 25.3 (d), 23.7 (t), 22.7 (q). MS-EI: 312 (M+).
4-(2-Difluoromethoxy-5-pentanoylphenoxy)piperidine-1-carboxylic Acid tert-Butyl Ester
(5zg)
Yield: 10%. 1H NMR (CDCl3): 7.62 (1H, d, J = 1.6 Hz), 7.55 (1H, dd, J = 1.6 and 8.4 Hz),
7.23 (1H, d, J = 8.4 Hz), 6.61 (1H, t, J = 74.4 Hz), 4.60 (1H, m), 3.67 (2H, m), 3.40 (2H, m),
2.93 (2H, t, J = 6.8 Hz), 1.93 (2H, m), 1.80 (2H, m), 1.71 (2H, m), 1.47 (9H, s), 1.40 (2H, m),
0.96 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 199.1 (s), 154.7 (s), 148.9 (s), 145.0 (s), 135.3
(s), 122.1 (d), 122.0 (d), 115.8 (triplet, J = 259 Hz, d), 115.2 (d), 79.7 (s), 74.1 (d), 40.5 (t),
38.2 (t), 30.4 (t), 28.4 (q), 26.5 (t), 22.4 (t), 13.9 (q). MS-EI: 371 [M – C4H9 (t-Bu) + H]+, 354
[M – C4H9O (t-BuO)]+, 327 [M – C5H9O2 (Boc) + H]+.
1-[4-Difluoromethoxy-3-(tetrahydropyran-4-yloxy)phenyl]-butan-1-one (5zh)
Colorless oil. Yield: 59%. 1H NMR (CDCl3): 7.62 (1H, s), 7.55 (1H, d, J = 8.4 Hz), 7.23 (1H,
d, J = 8.4 Hz), 6.64 (1H, t, J = 74.4 Hz), 4.62 (1H, m), 3.98 (2H, m), 3.60 (2H, m), 2.92 (1H,
t, J = 7.2 Hz), 2.03 (2H, m), 1.84–1.74 (4H, m), 1.01 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3):
198.9 (s), 148.8 (s), 145.0 (s), 135.4 (s), 122.14 (d), 122.07 (d), 115.9 (triplet, J = 259 Hz, d),
115.3 (d), 73.5 (d), 64.9 (t), 40.4 (t), 31.6 (t), 17.8 (t), 13.8 (q). MS-EI: 314 (M+).
1-[4-Difluoromethoxy-3-(pyridin-2-yloxy)phenyl]butan-1-one (5zi)
Yield: 99%. 1H NMR (CDCl3): 8.08 (1H, m), 7.85–7.83 (2H, m), 7.71 (1H, m), 7.32 (1H, d,
J = 8.8 Hz), 7.03–6.99 (2H, m), 6.48 (1H, t, J = 73.6 Hz), 2.91 (2H, t, J = 7.2 Hz), 1.76 (2H,
m), 0.99 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 198.1 (s), 162.7 (s), 147.2 (d), 144.8 (s), 139.7
(d), 135.3 (s), 125.9 (d), 123.7 (d), 120.8 (d), 118.9 (d), 115.8 (triplet, J = 260 Hz, d), 111.2
(d), 40.4 (t), 17.6 (t), 13.8 (q). HRMS-ESI (+): calcd for C19H15NO2F, 308.1087; found,
308.1085.
1-(3,4-Bisdifluoromethoxyphenyl)-4-phenylbutan-1-one (5zj)
Yield: 63%. 1H NMR (CDCl3): 7.81 (1H, s), 7.77 (1H, dd, J = 2.0 and 8.4 Hz), 7.32–7.27 (3H,
m), 7.22–7.19 (3H, m), 6.59 (1H, t, J = 72.8 Hz), 6.56 (1H, t, J = 73.2 Hz), 2.93 (2H, t, J = 7.2
Hz), 2.72 (2H, t, J = 7.2 Hz), 2.08 (2H, m). 13C NMR (CDCl3): 197.6 (s), 145.9 (s), 141.9 (s),
141.4 (s), 135.1 (s), 128.48 (d), 128.45 (d), 126.5 (d), 126.1 (d), 121.9 (d), 121.2 (d), 115.52
(triplet, J = 262 Hz, d), 115.33 (triplet, J = 263 Hz, d), 37.5 (t), 35.0 (t), 25.5 (t). MS-EI: 356
(M+).
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Yield: 72%. 1H NMR (CDCl3): 7.85–7.82 (2H, m), 7.33 (1H, d, J = 8.0 Hz), 6.63 (1H, t, J =
72.8 Hz), 6.60 (1H, t, J = 73.2 Hz), 2.92 (2H, t, J = 7.2 Hz), 1.76 (2H, m), 1.01 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 197.9 (s), 145.8 (s), 141.9 (s), 135.1 (s), 126.5 (d), 121.8 (d), 121.1
(d), 115.6 (triplet, J = 261 Hz, d), 115.4 (triplet, J = 263 Hz, d), 40.3 (t), 17.5 (t), 13.6 (q). MS-
EI: 280 (M+).
1-(3,4-Bisdifluoromethoxyphenyl)-3-phenylpropan-1-on (5zl)
Yield: 46%. 1H NMR (CDCl3): 7.83–7.80 (2H, m), 7.30–7.24 (6H, m), 6.59 (1H, t, J = 74.4
Hz), 6.55 (1H, t, J = 72.8 Hz), 3.26 (2H, s), 3.06 (2H, s). 13C NMR (CDCl3): 196.8, 146.0,
141.9, 140.8, 134.9, 128.6, 128.4, 126.5, 126.3, 121.3, 121.2, 115.5 (triplet, J = 262 Hz), 115.3
(triplet, J = 263 Hz), 40.3, 0.9. MS-EI: 342 (M+).
1-(3,4-Bisdifluoromethoxyphenyl)-2-cyclohexylethanone (5zm)
Yield: 92%. 1H NMR (CDCl3): 7.84–7.81 (2H, m), 7.33 (1H, d, J = 7.6 Hz), 6.62 (1H, triplet,
J = 72.8 Hz), 6.60 (1H, triplet, J = 72.8 Hz), 2.79 (2H, d, J = 5.2 Hz), 1.96 (1H, m), 1.76–1.68
(5H, m), 1.31–1.15 (3H, m), 1.03 (2H, m). 13C NMR (CDCl3): 197.7 (s), 145.8 (s), 141.9 (s),
135.5 (s), 126.6 (d), 121.9 (d), 121.1 (d), 115.6 (triplet, J = 262 Hz, d), 115.4 (triplet, J = 263
Hz, d), 46.0 (t), 34.4 (d), 33.3 (t), 26.1(t), 26.0 (t). MS-EI: 334 (M+).
General Procedure for the Synthesis of 6 by Nucleophilic Addition to the Ketones 5
To ketones 5g or 5h (1 mmol) in THF (5 mL) was added dropwise 3-pyridyllithium or 3-
quinolyllithium at −78 °C. The resulting mixture was stirred overnight, during which time the
mixture was allowed to gradually warm from −78 °C to room temperature and quenched with
water. The aqueous layer was extracted three times with ethyl acetate. The combined organic
solution was dried over MgSO4, filtered, and evaporated. The residue was purified by flash
chromatography to afford 6.
1-[3-Methoxy-4-(pyridin-2-yloxy)phenyl]-1-pyridin-3-yl-pentan-1-ol (6a)
Yield: 36%. 1H NMR (CDCl3): 8.61 (1H, s), 8.32 (1H, s), 8.08 (1H, dd, J = 1.6 and 5.2 Hz),
7.79 (1H, d, J = 8.0 Hz), 7.63 (1H, m), 7.21 (1H, m), 7.15 (1H, d, J = 1.6 Hz), 7.05 (1H, d, J
= 8.4 Hz), 6.98–6.91 (2H, m), 6.86 (1H, d, J = 8.0 Hz), 4.27 (1H, s, br), 3.67 (3H, s), 2.27 (2H,
t, J = 7.2 Hz), 1.40–1.21 (4H, m), 0.86 (3H, t, J = 7.2 Hz). 13C NMR (CDCl3): 163.4 (s), 151.4
(s), 147.31 (d), 147.26 (d), 144.4 (s), 142.8 (s), 141.4 (s), 139.1 (d), 134.1 (d), 122.9 (d), 122.2
(d), 118.5 (d), 118.0 (d), 111.2 (d), 110.6 (d), 76.5 (s), 55.8 (q), 41.6 (t), 25.7 (t), 22.9 (t), 13.9
(q). MS-EI: 364 (M+).
1-[3-Methoxy-4-(pyridin-2-yloxy)phenyl]-1-quinolin-3-ylbutan-1-ol (6b)
Yield: 53%. 1H NMR (CDCl3): 8.90 (1H, d, J = 1.6 Hz), 8.27 (1H, d, J = 1.6 Hz), 8.13 (1H,
dd, J = 1.2 and 4.4 Hz), 8.07 (1H, d, J = 8.0 Hz), 7.83 (1H, d, J = 8.0 Hz), 7.71–7.62 (2H, m),
7.55 (1H, m), 7.16 (1H, s), 7.10–7.03 (2H, m), 6.94 (1H, m), 7.89 (1H, d, J = 8.4 Hz), 3.70
(3H, s), 2.53 (1H, s, br), 2.38 (2H, m), 1.47 (1H, m), 1.00 (1H, m), 0.97 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 163.5 (s), 151.7 (s), 149.9 (d), 147.5 (d), 146.8 (s), 144.0 (s), 141.9
(s), 139.3 (s), 139.2 (d), 132.1 (d), 1.3 (d), 1.0 (d), 128.1 (d), 127.5 (s), 126.8 (d), 122.5 (d),
121.8 (d), 118.7 (d), 118.1 (d), 111.3 (d), 110.8 (d), 77.3 (s), 56.0 (q), 44.2 (t), 17.1 (t), 14.4
(q). HRMS-ESI (+): calcd for C25H25N2O3, 401.1865; found, 401.1853 [M + H]+.
Synthesis of 3-{1-[3-Methoxy-4-(pyridin-2-yloxy)phenyl]-but-1-enyl}quinoline (7a)
To a solution of 6a (0.33 g, 0.8 mmol) in acetic acid (5 mL) was added dropwise concentrated
H2SO4 (0.3 mL). The mixture was heated at 80 °C for 1 h and then cooled and neutralized with
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saturated NaHCO3. The aqueous solution was extracted with ethyl acetate three times. The
combined organics were washed with brine, dried over MgSO4, filtered, concentrated. The
residue was purified by flash chromatography to afford 0.12 g (37%) of 7a as a mixture of Z-
and E-isomers. 1H NMR (CDCl3): 8.97 and 8.79 (1H, s), 8.20–7.49 (6H, m), 7.19–6.82 (5H,
m), 6.00–6.25 (1H, m), 3.71 and 3.68 (3H, s), 2.30 (1H, m), 2.17 (1H, m), 1.11 (3H, m). 13C
NMR (CDCl3): 163.6 (s), 163.5 (s), 150.1 (d0, 151.6 (s), 151.45 (s), 150.0 (d), 147.53 (d),
147.46 9d), 147.1 (s), 147.0 (s), 142.0 (s), 139.9 (s), 139.24 (d), 139.15 (d), 137.9 (s), 137.2
(s), 136.6 (s), 136.3 (d), 135.4 (s), 134.3 (d), 133.9 (d), 133.5 (d), 133.1 (s), 1.4 (d), 1.2 (d),
128.99 (d), 128.96 (d), 127.9 (d), 127.8 (d), 127.8 (s), 126.8 (d), 126.7 (d), 122.63 (d), 122.60
(d), 120.3 (d), 118.2 (d), 118.1 (d), 114.4 (d), 111.8 (d), 110.9 (d), 110.7 (d), 55.9 (q), 23.5 (t),
23.3 (t), 14.4 (q). HRMS-ESI (+): calcd for C25H23N2O2, 383.1760; found, 383.1742 [M +
H]+.
Synthesis of 8
To a solution of 6a (0.30 g, 0.80 mmol) in acetic acid (5 mL) was added dropwise concentrated
H2SO4 (0.3 mL). The mixture was heated at 80 °C for 1 h. After 6a was converted to 7a
completely, without workup the product was hydrogenated at room temperature overnight
using 10% Pd/C (0.03 g) as catalyst. The reaction mixture was neutralized with saturated
NaHCO3. The aqueous solution was extracted with ethyl acetate three times. The combined
organic solution was washed with brine, dried over MgSO4, filtered, and concentrated. The
residue was purified by flash chromatography to afford 0.11 g (38%) of 8 as a white solid, mp
56–58 °C. 1H NMR (CDCl3): 8.57 (1H, s), 8.44 (1H, d, J = 4.4 Hz), 8.11 (1H, dd, J = 2.0 and
5.2 Hz), 7.62–7.54 (2H, m), 7.20 (1H, m), 7.70 (1H, d, J = 8.0 Hz), 6.91–6.84 (4H, m), 3.91
(1H, t, J = 8.0 Hz), 3.70 (3H, s), 2.06 (2H, m), 1.38–1.24 (4H, m), 0.87 (3H, t, J = 7.2
Hz). 13C NMR (CDCl3): 163.4 (s), 151.4 (s), 149.34 (d), 147.37 (d), 147.20 (d), 141.6 (s),
140.8 (s), 140.1 (s), 138.9 (d), 134.9 (d), 123.2 (d), 122.6 (d), 119.8 (d), 117.8 (d), 111.4 (d),
110.4 (d), 55.7 (q), 48.5 (d), 35.0 (t), 0.8 (t), 22.3 (t), 13.7 (q).
Synthesis of 4-[3-Methoxy-4-(pyridin-2-yloxy)phenyl]-4-quinolin-3-ylbutan-2-one (11a) and 4-
(4-Hydroxy-3-methoxyphenyl]-4-pyridin-3-ylbutan-2-one (11b)
To compound 4h or 4i (0.50 mmol) in CH2Cl2 (20 mL) at room temperature was added
SOCl2 (0.75 mmol). After 45 min, the mixture was carefully poured into saturated NaHCO3
(5 mL). The layers were separated, and the aqueous phase was extracted with CH2Cl2. The
combined organic solution was washed with saturated NaHCO3 and brine, dried over
MgSO4, filtered, and concentrated. The thick yellow oil (9a or 9b) was used immediately in
the next reaction without further purification. To a solution of ethyl acetoacetate (0.60 mmol)
in THF at 0 °C was added sodium methoxide in portions. After the mixture was stirred for 30
min, a solution of 9a or 9b in THF was added dropwise. The mixture was stirred at room
temperature overnight and then poured into saturated NH4Cl. The layers were separated, and
the aqueous phase was extracted twice with ethyl acetate. The combined organic solution was
washed with 25% NH4OAc buffer and brine, dried over MgSO4, filtered, and concentrated to
provide crude 10a or 10b. 10a or 10b was dissolved in a mixture of THF/MeOH/H2O (3:1:1,
10 mL), and then 2 N LiOH (1 mL, 2 mmol) was added. The mixture was heated at 70 °C for
2 h. Volatile components were removed on the rotovap, and the residue was partitioned between
saturated NaHCO3 and ethyl acetate. The aqueous phase was extracted twice with ethyl acetate.
The combined organic solution was washed with brine, dried over MgSO4, filtered, and
concentrated. The residue was purified by flash chromatography to afford 11a or 11b.
11a
Yellow oil. Yield: 28%. 1H NMR (CDCl3): 8.86 (1H, d, J = 2.0 Hz), 8.11 (1H, dd, J = 1.2 and
4.4 Hz), 8.06 (1H, d, J = 8.4 Hz), 7.96 (1H, d, J = 2.4 Hz), 7.76 (1H, d, J = 7.2 Hz), 7.68–7.59
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(2H, m), 7.50 (1H, m), 7.07 (1H, d, J = 8.0 Hz), 6.93–6.84 (4H, m), 4.82 (1H, t, J = 7.2 Hz),
3.70 (3H, s), 3.31 (2H, d, J = 7.2 Hz), 2.14 (3H, s). 13C NMR (CDCl3): 205.5, 163.7, 152.1,
151.3, 147.6, 147.2, 142.0, 140.4, 139.1, 136.5, 133.7, 1.3, 1.1, 128.0, 127.7, 126.8, 13.2, 120.1,
118.1, 113.5, 110.8, 56.2, 49.6, 43.6, 30.5.
11b
Yellow oil. Yield: 24%. 1H NMR (CDCl3): 8.52 (1H, d, J = 2.0 Hz), 8.43 (1H, dd, J = 1.6 and
4.8 Hz), 7.52 (1H, d, J = 8.0 Hz), 7.20 (1H, m), 6.84 (1H, d, J = 8.0 Hz), 6.72–6.67 (2H, m),
6.15 (1H, s, br), 4.54 (1H, t, J = 7.6 Hz), 3.81 (3H, s), 3.17 (2H, d, J = 7.6 Hz), 2.11 (3H,
s). 13C NMR (CDCl3): 206.1 (s), 145.0 (d), 147.7 (d), 146.8 (s), 144.6 (s), 139.7 (s), 135.3 (d),
134.5 (s), 123.5 (d), 119.8 (d), 114.6 (d), 110.7 (d), 55.9 (q), 49.4 (t), 43.2 (d), 30.6 (q).
PDE Inhibition Assays
The enzymatic activities of PDEs were assayed using 3H-cAMP and 3H-cGMP as substrates.
39,40 The expression and purification of PDE has been described earlier.41 First, PDEs were
incubated with the reaction mixture of 50 mM Tris-HCl, pH 7.8, 10 mM MgCl2, and 3H-cAMP
or 3H-cGMP (40 000 cpm/assay) at 24 °C for 30 min. Then the reaction was terminated by
addition of ZnSO4 and Ba(OH)2. The reaction product 3H-AMP or 3H-GMP was precipitated
by BaSO4, while unreacted 3H-cAMP or 3H-cGMP remained in the supernatant. Radioactivity
in the supernatant was measured by liquid scintillation. The activity was measured at eight
concentrations of cAMP and cGMP, and each measurement was repeated three times. Vmax
and Km values were calculated by linear plots of Lineweaver–Burk (1/V vs 1/[S]) and Eadie–
Hofstee (V/[S] vs V)42 and also by nonlinear regression analysis as implemented in the program
DynaFit.43 For measurement of IC50, 10 concentrations of inhibitors were used under the
substrate concentration of one-tenth of KM and the suitable enzyme concentration. For the
potent inhibitors, a double or triple measurement was performed, while a single measurement
was carried out for the poor inhibitors
NMR Study of the Interaction of Inhibitors with PDE4D2 Protein
A reference 1H spectrum and a 2D NOESY (mixing time of 500 ms) spectrum were taken on
a Varian 800 MHz NMR using a 400 μM sample in 20 mM potassium phosphate (pH 7.1)
D2O buffer. A sample with a 1:80 molar ratio of the inhibitor to protein was made in 20 mM
potassium phosphate (pH 7.1) D2O buffer with concentrations of 800 μM 5i and 10 μM
PDE4D2. STD and trNOEsy (mixing time of 50 ms) experiments were performed. The sample
was subsequently diluted, and another STD spectrum was collected to test for nonspecific
binding.
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Structures of selected PDE4 inhibitors.
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General structures of potential inhibitors designed.
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Inhibitory effect of 5v (▲) and 5zf (■) against LPS-mediated TNF-α production, compared
with rolipram (●).
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Key residues in the binding site of rolipram (white), 5za (yellow), 5v (blue), and 5zf (red) to
PDE4.
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Binding profile of 5za and rolipram with PDE4D2 obtained from Ligplot analysis.
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Negative effect observed for a bulky substitution at 4-position: blue stick, 5f; gray stick, 5m.
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Docking conformation of 5za in the PDE4D active site.
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Comparison of sp2-hybridized ketone (blue stick, 5m) and sp3 alcohol (gray stick, 4l).
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Docking conformations of synthesized inhibitors in the PDE4D active site.
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Chemical structures for test set validation.
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Actual versus predicted pIC50 for CoMSIA 3D-QSAR model.
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(a) Reference 1D 1H NMR spectrum of 400 μM 5i with assignments indicated by letters on
the chemical structure. The peak for the proton in the 4-position of the piperidinyl group
(labeled “h” on the chemical structure) is buried under the water peak. Peak “i” was not assigned
and is believed to be a contaminant. (b) STD spectrum of 800 μM 5i with 10 μM PDE4D2
using a 50 Hz Gaussian saturation pulse train of 250 ms centered at 0.5 ppm. The protein
background was not subtracted or suppressed. The normalized STD percentages calculated
from the STD and reference spectra of 5i are superimposed on the chemical structure. Both
spectra were collected using a Varian INOVA 800 MHz NMR instrument equipped with a
cryogenic probe. The water peaks in the center of the spectra were removed for clarity.
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The 2D NOESY spectrum of 800 μM 5i and 10 μM PDE4D2 with a 50 ms mixing time is
shown. The cross peaks have positive intensities (i.e., negative NOEs), which indicate that
5i binds PDE4D2.
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a (a) CClF2COOMe, Cs2CO3, DMF; (b) (i) method A, R1OH or R2OH, PPh3, t-
BuO2CN=NCO2-t-Bu, THF; method B, R1Br or R2Br, CsCO3, DMF; (c) R3Li or R3MgBr,
THF, −78 °C; (d) PCC, DCM; (e) R4Br, n-BuLi, THF, −78 °C; (f) AcOH, H2SO4, 80 °C; (g)
H2, Pd/C, room temp.
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a(a) SOCl2, DCM; (b) ethyl acetoacetate, CH3ONa, THF; (c) LiOH, THF/MeOH/H2O.
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Table 5
Actual pIC50, Estimated pIC50, and Residual Values of Molecules Used for CoMSIA
compd actual pIC50 estimated pIC50 residual
4b 2.82 3.15 −0.33
4c 3.27 3.15 0.12
4d 3.28 3.39 −0.11
4e 3.40 3.23 0.17
5i 3.99 3.85 0.14
5f 4.00 3.92 0.08
5a 4.03 4.15 −0.12
11b 4.10 4.02 0.08
5d 4.15 4.10 0.05
5c 4.22 4.30 −0.08
5j 4.35 4.09 0.26
5zj 4.36 4.49 0.13
5zi 4.40 4.14 0.26
5b 4.54 4.27 0.27
5e 4.62 4.45 0.17
4l 5.00 5.35 −0.35
8 5.00 4.99 0.01
11a 5.22 5.24 −0.02
5zm 5.28 5.60 −0.32
5k 5.46 5.77 −0.31
5q 5.59 6.08 −0.49
5r 5.59 5.78 −0.19
5o 5.64 5.98 −0.34
5zg 5.66 5.51 0.11
5p 5.72 5.54 0.18
5zb 5.96 6.34 −0.38
5l 6.14 5.88 0.26
5zc 6.18 6.37 −0.19
5ze 6.20 6.43 −0.23
5zl 6.30 6.07 0.23
5s 6.39 6.90 −0.01
5n 6.40 6.25 0.15
5u 6.42 6.21 0.21
5zh 6.46 6.39 0.07
5m 6.7 6.06 0.14
5zd 6.74 6.31 0.43
5t 6.75 6.99 −0.24
5za 7.21 7.20 0.01
5zf 7.66 6.80 −0.25
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compd actual pIC50 estimated pIC50 residual
5v 7.74 7.48 0.26
Test set rolipram 6.26 6.87 −0.61
s1 4.97 4.56 0.41
s2 5.51 6.12 −0.61
s3 7.55 7.93 −0.38
s4 4.43 4.82 −0.39
s5 6.40 7.01 −0.61
s6 7.15 6.54 0.61
s7 6.19 7.01 −0.82
s8 5.80 5.82 −0.02
s9 6.70 7.1 −0.40
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